

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 035 209 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
13.09.2000 Bulletin 2000/37

(51) Int Cl.7: **C12N 15/86, C12N 7/01,
C12N 5/10, A61K 39/00,
A61K 39/145, A61K 48/00**

(21) Application number: **99104519.6**

(22) Date of filing: **06.03.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- **Flick, Ramon**
13793 Västerhaninge (SE)
- **Menke, Anette**
35037 Marburg (DE)
- **Azzey, Mayra**
35394 Giessen (DE)

(71) Applicant: **ARTEMIS Pharmaceuticals GmbH**
51063 Köln (DE)

(74) Representative:
Helbing, Jörg, Dr. Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner,
Postfach 10 22 41
50462 Köln (DE)

(72) Inventors:
• **Hobom, Gerd**
35392 Giessen (DE)

(54) **Stable recombinant influenza viruses free of helper viruses**

(57) The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; wherein

- (a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or
- (b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of

the standard viral genes in sense orientation and a foreign, recombinant gene in antisense orientation, or *vice versa*, in overall convergent arrangement.

The present invention further provides a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising said recombinant influenza virus; and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.

EP 1 035 209 A1

Description

[0001] The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene (s), which is genetically stable in the absence of any helper virus; a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising said recombinant influenza viruses; and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.

[0002] Redesigning influenza virus into a vector system for expression of foreign genes similar to what has been achieved in several other thoroughly studied viruses such as adenovirus, retrovirus, Semliki Forest virus or Rabies virus has the advantage of an industrially well established mode of cheap propagation for influenza in fertilized chicken eggs leading to rather high titers (above 10^{10} /ml). On the other hand none of its genes may be deleted from the influenza genome according to our present knowledge, and give room for large-size foreign insertions. Only small fragments of foreign polypeptide chains such as B cell epitopes (10 to 15 amino acids) may be inserted into selected positions within two of the viral proteins, i.e. in exchange for one of the variable antigenic regions located at the surface of hemagglutinin (Muster et al., Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69 (11), 6678-6686 (1995)), or into the stalk sequence of viral neuraminidase (Garcia-Sastre and Palese, The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. Virus Res. 37, 37-47 (1995)), and be stably maintained as functional fusion proteins. Constructs of this kind turned out to be useful for experimental vaccination in a few cases studied, but only rather few clearly defined epitope sequences (of ten to twelve amino acids each) are known today, and some of them might also be misfolded within such restricted fusion protein positions, or in other cases interfere with the correct tertiary structure and function of their host polypeptide chains.

[0003] Incorporation of a full-size foreign protein into influenza via reverse genetics, encoded by an independent ninth vRNA molecule in addition to its regular set of eight standard vRNA segments is without special provisions only transiently possible (Luytjes et al., Amplification, expression, and packaging of a foreign gene by influenza virus. Cell 59, 1107-1113 (1989); Enami et al., An influenza virus containing nine different RNA segments. Virology 185, 291-298 (1991)). In the absence of a continuous selective pressure any additional recombinant vRNA segment cannot be stably maintained as long as a wildtype promoter sequence is used on that ninth vRNA segment, and it will inadvertently be lost after few steps of propagation. Using a different system of influenza reverse genetics developed in our laboratory (Zobel et al., RNA polymerase I catalysed transcription of insert viral cDNA. Nucleic Acids Res. 21, 3607-3614 (1993); Neumann et al., RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202, 477-479 (1994)), which was built around *in vivo* synthesis of recombinant vRNA molecules by cellular RNA polymerase I transcription of the respective template cDNA constructs, promoter-up mutations have been designed by nucleotide substitutions (Neumann and Hobom, Mutational analysis of influenza virus promoter elements *in vivo*. J. Gen. Virol. 76, 1709-1717 (1995)). When these are attached to a recombinant ninth vRNA segment its increased transcription and amplification rate will not only compensate for the losses suffered spontaneously, but even cause accumulation of the foreign vRNA segment during simple viral passaging, in the absence of any selection. However, due to its over-replication relative to all of the regular influenza vRNA segments (which of course are connected to wild-type promoter sequences) after catching up with the others the foreign segment will become over-abundant. This increasingly will result in viral particles that have incorporated several copies of recombinant vRNA, but no longer have a full set of all eight standard segments incorporated among an average of about 15 vRNA molecules present within a virion. Such particles are defective and will not result in plaque formation, hence after an initial increase of recombinant viral particles during the first steps of propagation a dramatic decrease is observed, usually at the third or fourth step of viral passaging, depending on the size of the recombinant vRNA and the level of the promoter-up mutation attached. A balanced situation with regard to the insert length and the level of promoter activity can be achieved, and has been propagated in a particular case over 11 passages, with essentially stable levels of recombinant viruses among a majority of helper viruses (around 80%) during these steps. If a full-level promoter-up mutation is used (1104 or the new variant 1920, see below) a balanced-level propagation is reached in conjunction with a recombinant vRNA size of 4000 nucleotides (unpublished).

[0004] In all of these preparations, both in transiently achieved increased yields (up to 40% of recombinants after three or four steps of viral passage), and in a balanced propagation of recombinant influenza viruses (10 - 20%) the respective viral progeny inadvertently constitute mixtures with a majority of non-recombinant helper viruses. These result both from a statistical mode of packaging vRNA molecules into a virion (the ninth segment may not be co-packaged), and from the fraction of cells solely infected by helper virus. The problems of fractional yields and of instability during viral propagation of recombinant influenza are the problems to be solved with the present invention.

[0005] Starting out from two observations in this laboratory which are discussed below and which concern two hitherto unsuspected properties of influenza viral RNA polymerase in its interaction with terminally adapted influenza-specific RNA molecules, a new technique for the construction of stable recombinant influenza viruses was found.

[0006] As previously described in WO 96/10641 plasmid constructs are designed to generate influenza vRNA-like molecules *in vivo* by cellular RNA polymerase I transcription following plasmid DNA transfection into tissue culture cells, and to this end contain flanking rDNA promoter and terminator elements, externally located relative to any cDNA constructs in between. The resulting recombinant vRNA molecules are designed to contain 5' and 3' recognition sequences for influenza viral RNA polymerase, which however carry up to five nucleotide substitutions (in promoter-up mutant PHL1920) resulting in a substantial increase of expression over wildtype influenza promoter levels. While recombinant pseudoviral RNA is initially transcribed by RNA polymerase I, further amplification and mRNA transcription depends on the presence of viral RNA polymerase and viral nucleoprotein in the cell, which generally are provided by infection of a helper virus. As a consequence the progeny viral yield will constitute a mixture of recombinant viruses together with a majority of wild-type helper viruses.

[0007] In the new technique the recombinant vRNA-like molecules as transcribed by RNA polymerase I are constructed as ambisense RNA double segments, with one reading frame (an influenza gene) in sense and a second one (a foreign gene) in anti-sense orientation, or vice versa. In such constructs both reading frames will be expressed via the cap-snatching mode, even if at different levels. Again, infection by helper virus is required to provide the necessary viral early and late proteins for genetic expression and virion packaging. However, the particular helper virus used in the new method is a recombinant virus carrying 2x2 specifically designed ribozyme targets inserted into the flanking non-coding sequences of one of its eight vRNA segments. The viral segment chosen to become ribozyme-sensitive is always identical to the one used in constructing the recombinant ambisense RNA molecule, as the viral carrier gene is in covalent linkage with an additional foreign gene.

[0008] Recombinant influenza viruses produced in this way through RNA polymerase I transcription of an ambisense viral RNA molecule followed by infection with that specifically designed type of ribozyme-sensitive helper virus will carry one of the influenza genes twice, once within that ribozyme-sensitive helper vRNA segment, and a second time within the ribozyme-resistant ambisense segment. Recombinant viruses of this type are again obtained initially only as a mixture together with a majority of non-recombinant helper viruses. A progeny viral passage through tissue culture cells (293T) which before have been transiently transfected with plasmid constructs expressing the respective double-headed ribozyme will (in one step) inactivate the ribozyme-sensitive segment by a factor of up to 100. One or two rounds of such ribozyme treatment *in vivo* will at the same time (a) purify the recombinant virus from its non-recombinant helper contaminants, and (b) delete the sensitive vRNA helper segment from within the initial (additive) recombinant virus.

[0009] As a result recombinant influenza viruses are isolated along this several-step procedure, which are free of contaminating helper viruses and carry seven regular and one ambisense vRNA segments, all in a balanced replication mode. Their recombinant nature is stably maintained because of a covalent junction between one of the viral genes and the full-size foreign gene inserted, a situation achieved here for the first time, via constructing an influenza ambisense RNA segment. The whole procedure is independent of any (selectable) phenotype, and can be applied to either of the eight influenza vRNA segments. After establishing a first ambisense vRNA segment carrying a single foreign gene it can also be repeated all over for inserting a second foreign gene within another ambisense RNA segment of the same constitution in principle.

[0010] Stable recombinant viruses of the type described can be used for cheap propagation in fertilized eggs, either for production of those recombinant viruses themselves or for production of foreign proteins or glycoproteins encoded by them, and hence find application in (glyco)protein production or in providing vector systems for somatic gene therapy or in being used as vaccination agents.

[0011] Thus, the present invention provides

(1) a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus, wherein

(a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or

(b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or *vice versa*, in overall convergent arrangement;

(2) a method for the production of recombinant influenza viruses as defined in (1) above comprising

(a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,
 (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA segments, and
 (c) thereafter selective vRNA inactivation through ribozyme cleavage;

(3) a method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising

- (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;
 - (b) followed by infection of an influenza wildtype strain;
 - (c) thereafter amplification through simple steps of viral propagation; and
 - (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing ribozyme type 2, followed by plaque purification;
- said method being suitable for the construction of an influenza carrier strain required for step (b) of (2) above;

- (4) a ribozyme-sensitive influenza carrier (helper) strain obtainable by the method of (3) above;
- (5) a pharmaceutical composition comprising a recombinant virus as defined in (1) above;
- (6) use of a recombinant virus as defined in (1) above for preparing a medicament for vaccination purposes;
- (7) use of a recombinant virus as defined in (1) above as vector systems in somatic gene therapy, for transfer and expression of foreign genes into cells (abortively) infected by such viruses, either in *ex vivo* or *in vivo* application schemes; and
- (8) a method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus as defined in (1) above as expression vector.

[0012] Moreover, the invention provides a method for preventing/treating influenza utilizing a recombinant virus as defined in (1) above, i.e., a vaccination method utilizing said recombinant virus.

[0013] According to the present invention "influenza virus" embraces influenza A virus, influenza B virus and influenza C virus. A preferred recombinant virus of the invention is where one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged into foreign glycoprotein(s) or into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.

[0014] Further preferred recombinant viruses of the invention are where the terminal viral RNA sequences, which are active as the promoter signal, have been varied by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence.

[0015] Further preferred embodiments of the invention are set forth herein below.

A. Construction of influenza helper virus strains carrying ribozyme target sequences in flanking positions within either of the vRNA segments

[0016] A.1. Influenza RNA polymerase will initiate transcription and replication from promoter structures located at internal positions in an RNA molecule, not only from the natural position at both ends of a vRNA molecule:

[0017] This is true in particular for promoter-up variants in RNA-internal location due to their enhanced binding affinity for viral polymerase. Not only 3' end extensions are tolerated in RNA-internal promoter recognition (Fig. 1), but also 5' extensions as well as extensions at both ends of the RNA template molecule, containing noncomplementary as well as complementary sequence, i.e. potentially present as a double-stranded extension. Finally, also an extension by way of duplication of the promoter sequence (active or inactivated) leads to mRNA transcription and CAT expression, initiated from the active pair of 5' and 3' promoter halves, irrespective if in external or in internal or even in an oblique localization (active 5' promoter sequence in external, active 3' promoter sequence in internal position, or vice versa). RACE-determination of the resulting 5' and 3' ends of viral mRNA and cRNA, i.e. the products of transcription and replication reactions for several of the extended template vRNA constructs proves an exact recognition and sequence-specific initiation at a position equivalent to regular 3' position $\bar{1}$: all of the various template extensions are lost in every product RNA molecule, most likely after only one round of replication.

[0018] A.2. Bicistronic (tandem) vRNA molecules carrying an additional 3' specific promoter sequence in a central position between its two genes can be used for an indirect selection method for recombinant influenza viruses:

[0019] The method described is applicable for any foreign gene (e.g. CAT) without a selection potential of its own, if inserted into the distal mRNA position (proximal vRNA position, in anti-sense orientation) behind a carrier gene (e.g. GFP) in the proximal mRNA position, able to serve as a transient selection marker. The carrier gene which is used for selection will get lost spontaneously during further propagation. These constructs are equivalent to a 3' extension of the template vRNA by a full-size gene of 750 nucleotides up to a second 3' promoter sequence, in terminal location.

While in the set of experiments shown in Fig. 2 the external 3' promoter sequence is maintained throughout as the same promoter-up variant (1104), the internal 3' promoter sequence has been varied to include a full-level promoter-up variant (pHL2270, containing promoter mutant 1104), a medium-level promoter variant (pHL2350, promoter mutant 1948), a wildtype promoter construct (pHL2629), and a construct carrying an unrelated central sequence in an otherwise identical design (pHL2300).

[0020] Due to the presence of two 3' promoter sequences in conjunction with a single 5' promoter sequence an alternating interaction between them will constitute one or the other active promoter structure (see Fig. 3). While the external location with an adjacent RNA 3' end may have a structural advantage, this appears to be compensated by the shorter distance in an interaction between the 5' sequence and the central 3' sequence in constituting the internal promoter, such that the competition between the two primarily reflects the various internal 3' promoter allele sequences used, compare Fig. 2B and activity ratios indicated above and below the lanes. Translation of the mRNA-distal gene (CAT) is only observed following an internal initiation at the bicistronic vRNA template, resulting in a spontaneous deletion of the mRNA-proximal (vRNA-distal) gene, GFP, compare right half of Fig. 3. In complementary analyses GFP fluorescence is observed initially for all of the bicistronic constructs, but gets lost on a faster rate from pHL2270 transfected and influenza infected cells (not shown), and will stay unchanged in pHL2300-treated cells. The indirect selection system based on bicistronic (tandem) molecules as designed here and demonstrated for reporter genes GFP and CAT can be used for any other gene without distinct phenotype upon insertion behind an unrelated carrier gene with properties useful in selection. - In employing that technique an initial phase of (repeated) positive selection for infected cells expressing that proximal trait (e.g. by FACS or by magneto-beads) will be followed by a second phase with negative selection, i.e. against that fraction of infected cells still exposing the same property.

[0021] A.3. Isolation of an influenza strain designed to carry 2x2 flanking ribozyme target sequences at the 5' and 3' end of vRNA segment 4 coding for hemagglutinin:

The above scheme for an indirect selection of any foreign recombinant gene behind a proximal carrier gene is further modified by deleting the carrier gene altogether. Instead, both 3' terminal promoter sequences (mutant and wildtype) follow each other at a short distance, separated only by a specific, repetitive ribozyme target sequence, - different from other target sequences to be described further below. The cDNA insert following after the second 3' promoter sequence consists mainly of a regular hemagglutinin (H7) coding sequence, however both the 5' and 3' vRNA terminal regions of the insert carry that other ribozyme target sequence (different from the first target sequence mentioned above) inserted in either location in tandem duplication (pHL2969, see Fig. 14).

[0022] Due to a superior replication supported by the promoter-up variant located in 3' external position the recombinant HA segment attached to that promoter sequence will become enriched during the first steps of viral propagation, while the originally dominating HA segment of the helper virus which is under control of a wildtype promoter sequence is consecutively reduced and finally is no longer detectable among viral progeny. This result is documented by RT-PCR analysis of consecutive viral populations as obtained in that stepwise propagation procedure, see Fig. 4.

[0023] In the next step the viral lysate is twice passaged via infection of cell culture cells (293T) that before have been DNA-transfected by plasmid pAM403 (Fig. 15). This construct has been specifically designed to express a hammerhead ribozyme with flanking sequences complementary to the repetitive GUC-containing target sequence, as present twice in between the external and internal 3' promoter signals in the recombinant HA vRNA segment, see Fig. 5. In this way the extra promoter sequence is cut off from the finally resulting recombinant HA vRNA. Its promoter-up activity was useful in achieving an initial increase in the concentration of recombinant HA vRNA over wildtype HA vRNA, and in finally excluding the latter from further propagation. However, for the same reason that high activity of the promoter variant will cause instability in the resulting viral progeny, and an effective 'substitution' at this time through ribozyme cleavage by the internally located promoter signal, wild-type or slightly improved, will restore stability to the progeny viruses, with all of their eight vRNA segments now brought back in balance to each other. Due to the ribozyme cleavage site at 26 nucleotides 3' of the wild-type promoter sequence (see Fig. 5), in the initial stage that promoter signal is situated in a vRNA-internal location, extended by a 3' terminal sequence of 26 nucleotides. According to the data presented in Fig. 1 this should cause a transient slight reduction in activity, resulting however in one step in regular viral mRNAs and cRNAs, with any initially remaining extra sequence being lost from the finally resulting recombinant HA vRNA.

[0024] Progeny viruses still carrying an external promoter-up sequence (before ribozyme treatment or due to incomplete reaction) will not cause any plaque, due to over-replication of one vRNA segment relative to all others which results in a high load of defective particles. However, progeny viruses which have lost that external promoter element due to ribozyme cleavage will yield regular plaques due to a balanced mode of replication for all eight wild-type or recombinant vRNA segments. Hence plaque purification is used for isolating a pure influenza viral strain carrying 2x2 ribozyme targets in its recombinant HA vRNA segment, with its termini reduced to the wild-type promoter sequence. The nature of the viral strain isolated has been confirmed in this regard by RT-PCR analysis, see Fig. 4.

[0025] The above isolation procedure resulting in influenza viral strains carrying 2x2 flanking ribozyme target sequences has been performed twice for the HA coding segment (segment 4) to obtain two different isolates with regard

to the orientation of the ribozyme target sequences. In one of the isolates (vHM41, see SEQ. ID NO: 3) the tandem target sites have been inserted into the HA vRNA non-translated sequence both in 5' and 3' location, while according to the second design that 5' tandem target sequence has been included in an inverted orientation, such that it is now present in the cRNA 3' sequence instead (vHM42).

[0026] In another experiment the same procedure was used to isolate an influenza strain carrying 2x2 tandem target sites within the 5' and 3' flanking positions of segment 8 vRNA, i.e. coding for genes NS1 and NS2 (vHM81; see SEQ. ID NO:4). And in principle the same could be done for any other influenza segment, in particular since only the reading frame cDNA sequence has been exchanged from HA to NS, with all of the flanking elements directly responsible for that procedure remaining in place, unchanged.

[0027] A.4. Ribozyme cleavage and vRNA segment exchange using ribozyme-sensitive influenza strains as helper viruses:

In an initial model experiment a range of ribozyme type and target site locations was probed in designing a series of CAT reporter gene vRNA constructs (analysed in the presence of a surplus of wildtype helper virus) in 293T cells. While all of the ribozyme constructs adhered to the hammerhead model, with 10 to 12 nucleotides of complementary sequence flanking on either side of the GUC target site, these ribozyme constructs varied from monomer to dimer to trimer repetitions. Ribozyme containing mRNAs were synthesized *in vivo* via the basic vector plasmid pSV2-*neo*, i.e. using the efficient p_{SVe} RNA polymerase II promoter element for expression, and the SV40 origin signal for plasmid amplification, in a cell line (293T or cos-1) with an incorporated SV40 T antigen gene. In addition the pSV2-*neo* mRNA includes the small, 63 nucleotide intron sequence of the SV40 early mRNA which is supposed to be spliced very slowly, thereby extending the pre-mRNA half-life in the nucleus. Each of the pSV2-*neo*-ribozyme plasmid constructs was transfected into 293T cells. Thereafter, recombinant viruses containing dimer target sites either near one end of the molecule only, or near both ends have been used for infection of the transfected cells. Relative activities of ribozyme constructs versus vRNA target sites have been measured via inactivation of CAT acetyl transfer rates in the cell lysates obtained at 8 h post infection (Fig. 6). The highest activities were observed for dimer ribozymes acting on vRNA molecules carrying 2x2 target sequences on both ends of the molecule, either in vRNA 5' and 3' location, or in vRNA 3' and cRNA 3' location, i.e. with an inversion of the target site sequence at the vRNA 5' end. Consequently, the two constructs carrying tandem ribozyme double targets within both of their non-translated vRNA flanking sequences have been used in the design of ribozyme-sensitive influenza virus strains as described above, with both variants isolated for segment 4 (HA), and one of them for segment 8 (NS). In complementary correspondence the hammerhead ribozyme plasmid used has also been constructed as a double-headed structure with flanking sequences as shown in Fig. 7 (pAM424; for its detailed structure, see Fig. 16).

[0028] The three target site-containing influenza strains isolated as described above have been analysed for their sensitivity against ribozyme cleavage by infection of 293T cells, which had been DNA-transfected 18 h earlier by ribozyme-producing plasmid pAM424, at DNA-transfection rates between 60 and 70 % (as observed in parallel transfections using GFP-expressing plasmid pAM505). Inactivation rates in these one-step control experiments were between 90% and 99% for all three ribozyme-sensitive strains, in their extent mainly depending upon the actual DNA-transfection rates achieved in individual experiments.

In the next step both isolates of HA-coding ribozyme-sensitive viruses, vHM41 and vHM42, have been used in marker-rescue experiments. Here, 293T cells have been first DNA transfected by HA-variant cDNA construct pHL2507 (see Fig. 17), followed after 18 h by vHM41 or vHM42 virus infections at moi 1. The resulting viral supernatant containing e.g. a mixture of ribozyme-sensitive vHM41 carrier virus and pHL2507/vHM41 recombinant virus is propagated in an intermediate step on MDCK cells, which also results in an increase in the fraction of recombinant viruses. Thereafter the resulting virus-containing supernatant is passaged through 293T (or cos-1) cells, which in advance have been transiently transfected by ribozyme-producing pAM424. As may be concluded from the above experiment (Fig. 6) and shown in Fig. 8 vHM41- or vHM42-derived ribozyme-sensitive HA vRNA segments are expected to be inactivated by pAM424-produced ribozyme down to a remaining level of about 1% to 10% (mainly present within cells that are infected, but not DNA-transfected).

[0029] Instead, the substitute HA vRNA which originated from pHL2507 plasmid DNA (ribozyme-resistant) becomes exclusively incorporated into progeny virions. For further purification and viral propagation these have been passaged a second time through 293T cells, again in advance DNA-transfected by pAM424, and after another amplification step on MDCK cells the resulting viral preparations have been used for RT-PCR analysis. The resulting viral populations in these marker rescue experiments only contain HA-vRNA molecules derived from pHL2507, which in their PCR analyses are of intermediate size relative to wildtype HA-vRNA, and vHM41- or vHM42-derived HA-vRNAs, respectively.

[0030] Consequently, a set of ribozyme-sensitive influenza strains with targets inserted individually into every vRNA molecule may be used for such one-step marker rescue experiments in general, i.e. for vRNA segment exchange reactions performed in a directional way for any of the eight influenza vRNA segments, without requirement for a selectable change in phenotype (genetic marker).

B. Expression of two gene products from ambisense bicistronic influenza vRNA

[0031] B.1. The influenza cRNA promoter is active in antisense viral mRNA transcription according to the cap-snatching mode of initiation:

While the vRNA template of influenza virus is known to be active in viral mRNA as well as cRNA synthesis, the cRNA template has been described so far only to produce vRNA molecules, as a second step in viral replication. The potential activity of the cRNA promoter in initiating also viral mRNA transcription has not been analysed or even suspected so far, since no antisense (vRNA) reading frame can be detected in any of the viral RNA segments. Also, no U₆/U₆ template sequence element is present in any of the viral cRNAs in an adjacent position to its 5' promoter structure as is the case for all viral vRNAs. This element is known to serve as a template sequence for mRNA terminal poly-adenylation, in repetitive interaction. However, when both elements are provided through reconstruction of an artificial influenza cRNA segment: a reading frame in opposite orientation (CAT), and a U₆ template element in 5' adjacent location, CAT expression can indeed be observed, see pHL2583 (see Fig. 18) in Fig. 9. Similar to the vRNA promoter the cRNA promoter activity is improved by (the same) promoter-up mutations, which essentially consist of basepair exchanges according to the 'corkscrew' model. This model apparently also holds for the cRNA promoter structure as analysed in a stepwise manner in Fig. 9. While the cRNA promoter has to be superior over the vRNA promoter in its initiation of replication, since the vRNA/cRNA product ratio was determined to be around 10:1 (Yamanaka et al., *In vivo* analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA. Proc. Natl. Acad. Sci. USA 88, 5369-5373 (1991)), the cRNA promoter is observed to be inferior to the vRNA promoter in its initiation rate of transcription (compare pHL2583 with pHL1844 in Fig. 9), at least for all promoter variants tested so far.

[0032] A RACE analysis for determination of the 5' ends in pHL2583 cRNA promoter transcribed mRNAs proved this initiation to occur according to the cap-snatching mode, in complete equivalence to standard vRNA promoter controlled transcription initiation.

[0033] B.2. Development of ambisense influenza constructs for consecutive expression of two genes (GFP and CAT) from a single viral RNA:

For a bidirectional transcription and translation of influenza RNA segments the two reporter genes GFP and CAT have been arranged in opposite orientation to each other, and the flanking 5' and 3' promoter sequences (adhering to promoter-up variant 1104) had to be reconstructed to include a U₆ poly-adenylation element in either orientation in a 5' promoter adjacent position. This requirement necessarily resulted in a promoter-adjacent 5'-U₆/3'-A₆ complementary structure, both in the vRNA and cRNA terminal sequence (see Fig. 10), which had to be tested for its promoter activity, in either orientation. Therefore, the convergent pair of reporter genes GFP and CAT has been inserted in both orientations, such that CAT transcription is initiated by the vRNA promoter in one construct (pHL2960), and by the cRNA promoter in the other (pHL2989, Fig. 19), and vice versa for GFP expression from both ambisense constructs. In addition, also the CAT gene only has been inserted in either orientation between the 5' and 3' elements of that ambisense promoter, with CAT transcribed by the vRNA promoter in one case (pHL2959), and by the cRNA promoter in the other (pHL2957). The whole set of constructs allows for a direct comparison with corresponding reference constructs carrying a regular vRNA promoter (pHL1844) or cRNA promoter structure (pHL2583), i.e. carrying only the 5'-adjacent U₆ sequence element and no 3'-A₆ counterpart. The two groups of constructs also differ in insert size, since a single inserted gene roughly accounts for 750 nucleotides, the convergent set of two genes for 1500 nucleotides, with the distal half of both mRNAs in this case remaining untranslated, a situation unusual for influenza viral mRNAs.

[0034] As is demonstrated in Fig. 10B for CAT expression of the various ambisense constructs all of them are able to initiate transcription in both orientations, even if at different levels with regard to their vRNA and cRNA promoter-dependent expressions, and also with regard to the insert lengths and convergent arrangements of the GFP/CAT versus CAT-only constructs. Analysis of the GFP expression rates (not shown) yields complementary results, i.e. again vRNA promoter-controlled GFP expression is superior over cRNA promoter expression of GFP. Therefore, individual ambisense clones either show an asymmetric high expression of GFP and low expression of CAT (pHL2960) or vice versa (pHL2989), depending on their orientation of reading frames with regard to the external vRNA and cRNA promoter. Fig. 10C also demonstrates successful propagation of recombinant viruses containing ambisense RNA molecules, which proves survival through amplification, packaging into virions, and expression of both mRNAs in infected MDCK cells (including besides CAT also GFP expression).

[0035] B.3. Construction of a superior promoter-up mutation, pHL1920, to be used for improved rates of cRNA promoter expression in ambisense constructs:

An extended analysis of promoter variants, in particular of complementary double exchanges according to the 'corkscrew' model yielded among others variant pHL1920 (Fig. 20) with CAT activity rates considerably above (125-130% of) the rates observed for standard promoter-up variant '1104' (as present in pHL1844). The '1920' promoter-up variant consists of altogether 5 nucleotide substitutions relative to the wildtype promoter sequence, both in the 5' promoter element (2), and the 3' promoter element (3). The structure of this variant and the whole set of complementary double exchanges is presented in Fig. 11, together with the respective CAT activity measurements, in vRNA promoter con-

structs. vRNA promoter-up variants also show similarly improved expression in (ambisense) cRNA constructs, even if at generally lower levels than in vRNA constructs. cRNA promoter-up expression is observed at levels similar or somewhat (2x-5x) above the *wild-type* vRNA promoter rate. while vRNA promoter-up constructs show CAT expression rates increased up to 20 or 25 times the wild-type vRNA promoter level. In either case expression rates also depend on the size of the insert, with promoter activity rates decreasing with increasing lengths of the influenza RNA molecules to be transcribed.

[0036] B.4. Influenza recombinant viruses containing a foreign gene (CAT) in covalent ambisense linkage with one of the viral genes (HA, NS1/NS2):

The principle solution in designing stable recombinant viruses based on the new properties observed for influenza transcription and replication signals consists in constructing viruses which contain a foreign gene in covalent linkage with one of the (indispensable) viral genes, in ambisense bicistronic organization. Preferably the viral gene is connected to the cRNA promoter, while vRNA promoter expression is used for expression of the foreign gene at rates considerably above the viral mRNA synthesis. The promoter-up variant chosen for constructing the ambisense RNA segment intends to bring its cRNA promoter expression (approximately) into balance with all other viral gene expression levels, which are controlled by wild-type vRNA promoters located at the termini of the seven ordinary influenza segments; the respective choice has to take into consideration the overall length of the ambisense segment.

[0037] Isolation of the ambisense recombinant virus employs an RNA polymerase I-transcribed ambisense cDNA construct, which will give rise *in vivo* to ambisense cRNA-type molecules, see Fig. 12. The plasmid DNA transfection mixture used in this step with 293T cells in addition may or may not contain four 'booster' plasmids which under p_{CMV} -control produce the four early influenza proteins from non-viral mRNAs: NP, plus PB1, PB2, and PA, i.e. the three subunits of viral polymerase (Pleschka et al., A plasmid-based reverse genetics system for influenza A virus J. Virol. 70, 4188-4192 (1996)), which will increase in a pre-amplification step the copy number of that ambisense viral cRNA segment. At 18 h post transfection the 293T cells are infected by a ribozyme-sensitive influenza strain, e.g. vHM41, which will supply (again) early and also late viral RNAs. The resulting supernatant which contains a mixture of vHM41 carrier virus and vHM41-derived ambisense recombinant virus (nine vRNA segments) is then passaged directly or via an intermediate step of amplification on MDCK cells onto 293T cells that have in advance been DNA-transfected by ribozyme-producing pAM424. Here, the ribozyme-sensitive vRNA segment of vHM41 will be cleaved at its 2x2 target sites by pAM424 specific ribozymes. In recombinant viruses the vRNA gene lost in this way is re-supplemented through its presence within the ambisense segment. The virus-containing supernatant is passaged for amplification and further purification through ribozyme treatment a second time on 293T cells which again have been pretreated by pAM424 DNA transfection.

[0038] Absence of ribozyme-sensitive vRNA, and presence only of ambisense RNA in RT-PCR analysis at this stage allows for further amplification on MDCK cells and a final virus stock preparation on embryonated chicken eggs. CAT assays can be used to analyse for the presence and monitor the activity of this model foreign gene through the various steps of isolation and propagation as well as document technical improvements that might be worked out for one or more of the processive stages.

C. Examples for application of helper-free, stable recombinant influenza viruses

[0039] C.1. Incorporation of reporter gene GFP in NS/GFP or HA/GFP ambisense segments:

Recombinant viruses of this type will allow to follow-up on influenza infection instantly and continuously in individual infected cells, which may also be counted or documented by fluorescence photography or FACS sorting. With improved temperature resistance (Siemering et al., Mutations that suppress the thermosensitivity of green fluorescent protein. Curr. Biol. 6, 1653-1663 (1993)) GFP expression becomes visible at 2 h after infection and shows bright fluorescence after 4 h p.i., it will be possible to follow-up on the spread of viral infection by GFP fluorescence. Stable fluorescence in abortively infected cells e. g. observed in *ex vivo* treatment of dendritic cells similarly supports a follow-up on their reincorporation into animals; other genes may be incorporated by ambisense vRNA into dendritic cells in the same way.

[0040] C.2. Construction of glycoprotein CSFV-E2 carrying influenza, helper-free:

The glycoprotein E2 of CSF virus has been incorporated previously into influenza both as an HA-anchor fusion protein within the viral envelope, and as an additional, unstable ninth vRNA segment into its genome (Zhou et al.; Membrane-anchored incorporation of a foreign protein in recombinant influenza virions. Virology, 246, 83-94 (1998)). Stabilization is now achieved through an ambisense connection with either of the regular viral RNA segments (NS or HA) which also allowed to reach a level of 100% recombinant viruses instead of an hitherto only 20% (Fig. 13), since all carrier viruses are destroyed through ribozyme action, see Figs. 8 and 12. The helper virus containing preparation has already been used successfully as a vaccine against CSFV infection (antibody titers of 1:40000); the increase achieved in recombinant viruses allows a further improvement in that regard. Also (cost-effective) propagation in fertilized chicken eggs has become possible due to its stable incorporation of the foreign gene as a covalent ambisense construct.

[0041] C.3. Construction of hepatitis C glycoprotein-carrying recombinant influenza viruses as a candidate vaccine:

Hepatitis C virus is a close relative of CSF virus (hog cholera virus), and in particular its set of two glycoproteins, small-size E1 and larger-size E2, is closely related in structural detail and presumably also in function to the corresponding CSFV proteins. An incorporation of HCV-E2/HA fusion proteins into influenza viral envelopes has been achieved in analogy to the CSFV-E2/HA incorporation. In addition, incorporation of an anchor-fusion glycoprotein HCV-E1/HA or both together (in NS *and* HA ambisense junctions) allows further variations in constructing an influenza-based vaccine for hepatitis C. In analogy to CSFV-E2, neutralizing antibodies are expected to be directed against particular epitopes of HCV-E2, presented in essentially native conformation at the influenza viral envelope.

[0042] C.4. Stable incorporation of selected influenza T-cell epitopes in ambisense constructions:

Influenza infection is known to result in both, antibody production against that specific viral strain or indeed its epitopes that are located mainly at the surface of HA, and in an increase of specifically primed cytotoxic T-lymphocytes, stimulated by T-cell epitopes primarily located within the essentially invariable core structure of the NP protein. While the humoral response will result in life-long immunity against *that particular* strain of influenza or its epitope structures, the T-cell response will be lost or severely reduced some time afterwards, such that its specificity against influenza in general will fall below protective levels. One way in trying to increase that level of cellular immunity is to enhance the response or recruitment of influenza-specific CTL cells by increasing the level of T-cell epitopes in the infected cell and hence its presentation on the surface by MHC-I receptors. This is achieved by combining in an ambisense construct the HA gene and a series of repeated T-cell epitope sequences as present in the influenza NP gene, in a model design specific for the BALB/C mouse MHC-I allele. Here, the promoter-up expression rate is realized (in vRNA promoter-controlled initiation) for expression of the repetitive epitope polypeptide chain. Alternatively or in addition a controlled secretion of an interleukin can be achieved from recombinant influenza-infected cells, upon ambisense incorporation of the respective gene preferably into the NS segment. The interleukin to be chosen for this purpose (IL-12 or other) is selected to enhance the longevity of influenza-specific CTL cells or its conversion into corresponding memory cells. In this way an ambisense vaccine strain against influenza itself is achieved with expected protective capacity against influenza in general.

[0043] C.5. Exchange of influenza glycoproteins against foreign viral glycoproteins (VSV-G):

The 'marker rescue' experiment described above (section A.4.), i.e. an exchange of one HA gene (ribozyme-sensitive) for another (ribozyme-resistant) can also be used for an exchange of HA for an entirely different glycoprotein, such as the vesicular stomatitis virus G protein, as long as it is attached to the HA anchor segment. Effective incorporation depends always on that C-terminal tail sequence and its interaction with underlying matrix protein M1, and therefore, all constructions consist of fusion proteins in direct analogy to CSFV-E2. VSV-G with or without a foreign anchor sequence has been shown in several other viruses to be able to substitute for the original glycoprotein and to result in infectious viruses with VSV-G specific host-ranges (e.g. in retroviruses, rabies virus, measles virus). G protein in VSV itself as well as on the surface of foreign viruses is the only glycoprotein required for all of the consecutive steps in infection. Insertion of VSV-G instead of HA in recombinant influenza viruses leaves the second glycoprotein, neuraminidase, without any function, which then will get lost spontaneously from the recombinant viruses. This will further increase the capacity for an addition of foreign genes, beyond the gain resulting from an exchange of the larger HA for the smaller VSV-G, which might be used for an addition of ambisense constructs.

[0044] The invention is further illustrated in the accompanying figures.

Description of the figures

[0045]

Fig.1. 3' nucleotide extensions of influenza vRNA template molecules:

(A) Murine B82 cells have been transfected by plasmid cDNA constructs designed to be transcribed into influenza vRNA molecules by RNA polymerase I *in vivo*, followed after 20 h by standard FPV_{Bratislava} helper virus infection, at an moi of 1 to 3. In addition to reference plasmid pHL2024 (no extension), related cDNA constructs carrying extensions of 1 to 50 bp, and hence extended by 1 to 50 nucleotides at the resulting vRNA 3' ends were used in parallel transfections; template extensions are marked at the top of the figure. Cell lysates prepared at 8 h post helper virus infections were used for CAT reactions using in one round 50 pl of cell lysate each, and in further analyses 5µl and 0.5 µl of lysate (not shown). Relative yields were determined in comparison to reference plasmid pHL2024, as indicated below the figure, with calculations restricted to those CAT assays showing less than 40% of substrate consumption, in three or more independent experiments.

(B) Viral passage of B82 supernatants containing recombinant influenza virus onto MDCK cells, at an moi of 2 to 4, in average. Again at 8 h post infection cell lysates have been prepared and used for CAT assays. Relative yields as indicated below the figure have been determined in comparison to pHL2024 the same way

as in (A), using 0.5 μ l of cell lysate in each case. (The 50 μ l CAT assays as shown here and also in the following figures intend to give an immediate impression of relative activities at always the same level, while the actual measurement data as indicated below the lanes are obtained at various appropriate enzyme concentrations relative to reference pHL2024.)

Fig. 2. Propagation of recombinant influenza viruses with tandem bicistronic vRNA:

(A) General design of expression plasmids for transient bicistronic vRNAs coding for GFP in the mRNA-proximal, and for CAT in the mRNA-distal position. Among the functional elements indicated are the human RNA polymerase I promoter (p_{IH}) and murine rDNA terminator (t_l) sequences, both hatched, and the 5' and 3' vRNA promoter cDNA sequences, open and closed boxes, respectively. For the vRNA-internal 3' promoter signal three variant sequences have been inserted as indicated below (positions $\bar{1}$ to $\bar{15}$ refer to 3'-terminal nucleotides in the resulting monocistronic vRNAs).

(B) CAT assays as determined relative to pHL1844 (monocistronic CAT construct) after DNA transfection of 293T cells plus helper virus infection followed by one round of progeny viral propagation on MDCK cells are indicated *below* the lanes. Relative activities of the internal promoter sequences as indicated *above* the figure refer to measurements in a monocistronic *external* location of the same promoter variants (Flick *et al.*, Promoter elements in the influenza vRNA terminal structure, RNA 2, 1046-1057 (1996)). Control clone pHL2300 contains an unrelated, non-functional sequence in the central location in an otherwise identical plasmid construct.

Fig. 3. Tandem bicistronic vRNA sup-orting an alternative mode of tran-scription and replication initiation:

An additional internal 3' promoter sequence has been inserted in between both cistrons, in a vRNA-central position. Left half: bicistronic replication and transcription leading to (proximal) GFP expression. Right half: internal initiation resulting in monocistronic replication and transcription leading to (distal) CAT expression, and causing deletion of the GFP sequence from progeny molecules.

Fig. 4. Outgrowth of promoter-up recombinant vRNA versus wildtype vRNA segments in stepwise propagation of influenza virus:

RNA polymerase I transcription of transfected pHL2969 DNA results in influenza vRNA carrying (an external) promoter-up mutant '1104', and containing 2x2 ribozyme targets in flanking positions relative to its HA coding sequence. Another HA vRNA segment in wild-type configuration and originating from infecting FPV helper virus is also present in the recombinant virus preparation, initially (lane 1; 293T lysate) in surplus amounts, but reduced and finally lost entirely in consecutive steps of propagation (lanes 2 to 4; MDCK cell lysates), and in isolated strains after pAM403 ribozyme treatment for removal of the external '1104' promoter sequence (lane 5). Determination throughout by RT-PCR analyses using a pair of primers extending across the 5' inserted target site sequence, with 435 bp representing the recombinant HA segment, and 306 bp the wild-type sequence without an inserted target site sequence.

Fig.5. pAM403 ribozyme cleavage of pHL2969 derived vRNA molecules at specific target sites inserted between an external and an internal 3' promoter sequence:

The external promoter-up ('1104') signal is used for vRNA amplification within recombinant viruses and reduction of helper virus HA vRNA (Fig. 4), while the 'switch' to an internal wild-type signal guarantees stable replication of recombinant viruses. pAM403 hammerhead ribozyme RNAs are indicated in complementary binding to their target site sequences (12 and 10 nucleotides flanking the GU'C cleavage point) by straight lines flanking a central secondary structure symbol. vRNA-internal 2x2 ribozyme targets are marked by xx (see Fig. 7).

Fig. 6. Comparative cleavage analysis of model CAT vRNAs with tandem target sites in various flanking positions, by target-specific ribozymes:

293T tissue culture cells have been transiently DNA-transfected either by a single-headed hammerhead ribozyme (s), or a double-headed (d), or triple-headed (t) ribozyme cDNA construct, all specifically designed to hybridize to a tandem dimer target site sequence inserted in flanking positions into the CAT vRNA. All ribozyme RNAs have been expressed from the same pSV2-*neo* plasmid vector, including a pSV2-*neo* control construct without an inserted ribozyme cDNA sequence (c). At 20 h after DNA transfection (which reached 65% yield as measured by p_{CMV} -GFP transfection in parallel of the same cell culture) the 293T cells were infected by CAT recombinant viruses carrying tandem double target sequences either only in vRNA-3' position, or in both vRNA-3' and 5' positions, or in both vRNA-3' and cRNA-3' positions. Most effective among the s, d, or t-ribozymes were double-headed constructs, acting on 2x2 targets inserted in either of the two localizations described (lanes 6 and 10).

Fig. 7. Alignment of pAM424 double-headed ribozyme with one of their repetitive target sequences located within the 5' and 3' vRNA flanking regions:

The superior activity of ribozymes oriented against targets located in the 3' end of vRNA molecules over those present in the 5' end instead (not shown) is in agreement with the model for influenza vRNA transcription and replication (Lamb and Krug, Orthomyxoviridae: The viruses and their replication. In 'Virology' (B.N.Fields, D.M. Knipe, P.M.Howley, R.M.Chanock, J.L.Melnick, T.P.Monath, B.Roizman, and S.E.Straus, Eds.), 3rd ed., Vol. 1, pp. 1353-1395. Lippincott-Raven, Philadelphia (1996)), according to which influenza polymerase stays attached to the 5' end of the vRNA molecule throughout the entire or even several rounds of transcription, whereas the very 3' end repeatedly, in every initiation reaction serves as the template sequence, and consequently is no longer covered by polymerase. Superiority of a double-headed over a single-headed ribozyme has been determined earlier in this laboratory (A.Menke, Anti-Influenza Ribozyme: vRNA-Spaltung und intrazelluläre Aktivität. Dissertation Universität Giessen (1997)), but the substantial increase of vRNA inactivation rates upon incorporation of tandem target sites at both ends of the vRNA molecule instead of only one has been observed here for the first time, within that overall design.

Fig. 8: pAM424 ribozyme cleavage of resistant FPV wild-type HA vRNA and ribozyme-sensitive pHL2969-derived HA-vRNA in 293T cells infected by vHM41 after isolation from pHL2969-recombinant viral preparations. Lane 1: FPV infection of 293T cells, untreated; lane 2: FPV infection of 293T cells DNA-transfected by pAM424; lane 3: vHM41 infection of 293T cells, untreated; lane 4: vHM41 infection of 293T cells DNA-transfected by pAM424. RT-PCR analyses of purified viral progeny as in Fig. 4.

Fig. 9 Functional analysis of the influenza cRNA promoter structure:

(A) Schematic cRNA promoter ('1104') secondary structure according to the 'corkscrew' model; nucleotides involved in single or double nucleotide exchange are marked by their position.

(B) CAT analyses of 293T cell lysates after DNA transfection and FPV helper virus infection of cRNA promoter variants, in comparison to standard vRNA promoter-up mutant '1104' (pHL1844). Nucleotide substitutions divergent from the basic '1104' structure as present in pHL2583 or pHL2721 (see above) are indicated above the lanes, positions 3̄ or 8̄ as marked by a bar refer to cRNA positions counted from the 3' end. Relative CAT activities are marked below the lanes.

Fig. 10 Functional analysis of the vRNA and cRNA promoter in ambisense arrangement:

(A) Sequence organisation of the ambisense promoter cDNA construct carrying T_g/A₆ elements adjacent to the terminal sequence, and secondary structure predictions for the resulting cRNA and vRNA promoter signal.

(B) CAT expression data obtained from the cell lysates of 293T cell after plasmid DNA transfection and FPV infection, and (C) from cell lysates of MDCK cells after one step of viral passage. Indicated above the lanes are promoter/gene conjunctions: v = vRNA promoter; c = cRNA promoter.

Fig.11 Basepair substitutions according to the vRNA 'corkscrew' structure:

(A) 'Corkscrew' conformation of the vRNA promoter drawn against a schematic indication of interacting tripartite viral polymerase. Paired positions exchanged in individual experiments are indicated by numbers, nucleotides 3̄ or 8̄ are counted from the 3' end. pHL2024 containing promoter-up mutation '1104' is used as the reference construct (=100%) in all of the CAT assays, while pHL2428 represents the wild-type promoter structure.

(B) CAT expression data obtained after one step of viral passage in MDCK undiluted, and 50 fold diluted.

Fig. 12: Flow-chart of the isolation procedure for an ambisense recombinant influenza virus.

Fig. 13 Immuno-electron microscopy of purified influenza FPV/CSFV-E2-HA virions: Recombinant viruses exposing the foreign glycoprotein CSFV-E2 in their envelopes, which has been fused onto the HA anchor domain, are marked by anti-E2 monospecific antibody and by secondary gold-labelled (5nm) goat antibody. Recombinant viruses (16%) are present together with their FPV helper viruses.

Fig. 14: pHL2969; the exact sequence of the 4930 bps circular DNA is shown in SEQ.ID NO:1.

Fig. 15: pAM403; the exact sequence of the 5811 bps circular DNA is shown in SEQ. ID NO:2.

Fig. 16: pAM424; the exact sequence of the 5860 bps circular DNA is shown in SEQ. ID NO:5.

Fig. 17: pHL2507; the exact sequence of the 4610 bps circular DNA is shown in SEQ. ID NO:6.

Fig. 18: pHL2583; the exact sequence of the 3558 bps circular DNA is shown in SEQ. ID NO:7.

Fig. 19: pHL2989; the exact sequence of the 4343 bps circular DNA is shown in SEQ. ID NO:8.

Fig. 20: pHL1920; the exact sequence of the 3888 bps circular DNA is shown in SEQ. ID NO:9.

[0046] Hence, the present invention is based on two surprising findings, namely

1. influenza virus promoters are active when present internally in a gene;
2. the so-called cRNA, thought to be an intermediate in replication can be turned into a protein-encoding RNA by equipping it with a variant influenza virus promoter, described in the present invention.

[0047] These two observations were used to make ambisense constructs. This allows to package an additional, foreign gene into influenza virus particles. Such particles were made previously, by other methods, but proved to be unstable, and therefore useless. For use as a vaccine for example, a helper virus would have been needed as a stabilizer. Stabilization in the present invention is achieved by several means. These include the "balancing" of one of the two promoters in the ambisense bicistronic genetic construct with seven other vRNA wildtype promoters, while the additional promoter is used for high-rate expression of the foreign gene at various levels.

[0048] Thus, the present invention provides a system for expression of foreign proteins in higher eukaryotic systems. One system in particular is interesting, namely embryonated chicken eggs, as it allows cost-effective production in an automatable way (as used by most flu vaccine producers). The reason that this process is now possible, is that the foreign protein is part of a stable, engineered influenza virus particle. The virus can be designed also to rapidly monitor process improvements.

[0049] An excellent use is of course the use of the construct as a vaccine. The influenza virus particle is immunogenic and can now be equipped with foreign antigens, enabling for example the design and production of hepatitis C virus and HIV vaccines, but also of tumor vaccines. As the present invention shows, the foreign antigenic surface glycoprotein is "fused" to a C-terminal segment of influenza HA, and the antigen then is presented at the surface of influenza virus particles. In addition, these vaccines can now be made in the way standard flu vaccines are made, i.e., in embryonated chicken eggs.

EP 1 035 209 A1

SEQUENCE LISTING

<110> ARTEMIS PHARMACEUTICALS GmbH

5 <120> Stable Recombinant Influenza Viruses Free of Helper
Viruses

<130> 990383ep

10 <140>
<141>

<160> 9

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 4930

<212> DNA

20 <213> Influenza virus

<400> 1

	cgtacgaagc	ttctagaggg	attggctgag	acgaaaaaca	tatgctagag	ggattggctg	60
	agacgaaaaa	catatgctag	agcggccgcc	accgcggtgg	agctccagct	tttgttccct	120
25	ttagtgaggg	ttaattgcgc	gcaggcctag	ctagggtaaag	aaaaataccc	ttgtttctac	180
	taataacccg	gcggcccaaa	atgccgactc	ggagcgaaag	atatacctcc	cccggggccg	240
	ggaggtcgcg	tcaccgacca	cgccgcggcg	ccaggcgacg	cgcgacacgg	acacctgtcc	300
	ccaaaaacgc	caccatcgca	gccacacacg	gagcgcccg	ggccctctgg	tcaaccccag	360
	gacacacgcg	ggagcagcgc	cgggccgggg	acgccctccc	ggccgcccgt	gccacacgca	420
30	gggggcccgc	ccgtgtctcc	agagcgggag	ccggaagcat	tttcggccgg	cccctcctac	480
	gaccgggaca	cacgagggac	cgaaggccgg	ccaggcgcg	cctctcgggc	cgcacgcgcg	540
	ctcagggagc	gctctccgac	tccgcacggg	gactcgccag	aaaggatcgt	gacctgcatt	600
	aatgaatcag	gggataacgc	aggaagaac	atgtgagcaa	aaggccagca	aaaggccagg	660
	aaccgtaaaa	aggccgcgtt	gctggcggtt	ttccataggc	tccgcccccc	tgacgagcat	720
35	cacaaaaatc	gacgctcaag	tcagaggtgg	cgaaacccga	caggactata	aagataccag	780
	gcgtttcccc	ctggaagctc	cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	840
	tacctgtccg	cctttctccc	ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	900
	tatctcagtt	cgggtgtagg	cgttcgctcc	aaagctgggt	gtgtgcacga	accccccggt	960
	cagcccagacc	gctgcgcctt	atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	1020
40	gacttatcgc	cactggcagc	agccactgg	aacaggatta	gcagagcgag	gtatgtaggc	1080
	ggtgctacag	agttcttgaa	gtggtggcct	aactacggct	acactagaag	gacagtatct	1140
	ggtatctgcg	ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	1200
	ggcaaaacaa	ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	gattacgcgc	1260
	agaaaaaaag	gatctcaaga	agatcctttg	atcttttcta	cggggtctga	cgtcagtggt	1320
45	aacgaaaact	cacgttaagg	gattttggtc	atgagattat	caaaaaggat	cttcacctag	1380
	atccttttaa	attaaaaatg	aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	1440
	tctgacagtt	accaatgctt	aatcagtgag	gcacctatct	cagcgatctg	tctatttcgt	1500
	tcatccatag	ttgcctgact	ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	1560
	tctggcccca	gtgctgcaat	gataccgcga	gacccacgct	caccggctcc	agatttatca	1620
50	gcaataaacc	agccagccgg	aaggccggag	cgcagaagtg	gtcctgcaac	tttatccgcc	1680
	tccatccagt	ctattaattg	ttgccgggaa	gctagagtaa	gtagttcgcc	agttaatagt	1740
	ttgcgcaacg	ttgttgccat	tgctacaggc	atcgtgggtg	cacgctcgtc	gtttgggtatg	1800
	gcttcattca	gctccgggtc	ccaacgatca	aggcgagtta	catgatcccc	catgttgtgc	1860
	aaaaaagcgg	ttagctcctt	cggctcctcg	atcgttgtca	gaagtaagtt	ggccgcagtg	1920
55	ttatcactca	tggttatggc	agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	1980

EP 1 035 209 A1

	tgc	ttttctg	tgact	ggtga	gtact	caacc	aagtc	attct	gaga	atagt	tatg	cggcga	2040
	ccg	agttgct	cttgc	ccggc	gtca	acacg	gata	atacc	cgcc	acatag	caga	acttta	2100
	aaagt	gctca	tcatt	ggaaa	acgtt	ctctc	gggc	gaaaac	tctc	aaggat	cttacc	gctg	2160
5	ttg	agatcca	gttc	gatgta	acc	actcgt	gcac	ccaact	gatc	ttcagc	atctt	ttact	2220
	ttc	accagcg	tttct	gggtg	agca	aaaaa	gga	aggcaaa	atgc	cgcaa	aaagg	gaata	2280
	aggg	cgacac	ggaa	atggtg	aata	ctcata	ctct	tccctt	ttca	atatta	ttga	agcatt	2340
	tatc	aggggt	attgt	ctcat	gagc	ggatac	atatt	tgaat	gtatt	tagaa	aaata	aaacaa	2400
	aag	agtttgt	agaa	acgca	aaag	gccatc	cgtc	aggatg	gcct	tctgct	taatt	tgtatg	2460
10	cct	ggcagtt	tatgg	cgggc	gtcct	gcccc	ccacc	ctccg	ggcc	ggtgct	tcgca	acggt	2520
	caa	atccgct	ccc	ggcgat	ttgt	ctact	cagg	agagcg	ttc	accgaca	aaca	acagat	2580
	aaa	acgaaa	gccc	agtcct	tcga	ctgagc	cttt	cgttt	attt	gatgcc	tggc	agttcc	2640
	ctact	ctcgc	atggg	gagac	ccc	acactac	catc	ggcgct	acgg	cgttt	actt	ctgagt	2700
	tcgg	catggg	gtc	aggtggg	acc	accgcgc	tact	gccgc	agg	caaattc	tgtt	ttatca	2760
15	gacc	gcttct	gcgt	tctgat	ttat	ctgta	tcag	gctgaa	aatc	ttctct	catc	cgccaa	2820
	aac	agaagct	agcg	ccgat	cccc	aaaaaa	aaaa	aaaaaa	aaaa	aaaaaa	gagt	ccagag	2880
	tgg	ccccgcc	gttc	cgcc	ggg	ggggggg	ggg	ggggggg	acac	tttcgg	acat	ctggtc	2940
	gac	ctccagc	atc	gggggaa	aaaa	aaaaaa	caa	agtttcg	ccc	ggagtac	tgg	tcgacct	3000
	ccga	agttgg	gggg	gagtag	aaac	agggtg	gata	atcact	cact	gacgta	cg	ttgagcaa	3060
20	ctga	ctgaaa	tgct	ttagc	aact	gactga	aatg	cctgac	gtc	tttagca	aaag	cagggt	3120
	agata	atcac	tcact	gagtg	acat	ccacat	cgt	accagga	ttgg	ctgaga	cgaaa	aacat	3180
	attgt	accag	ggtat	ggctg	agac	gaaaaa	cat	attgtag	gtac	caaaat	gaac	actcaa	3240
	atcct	ggttt	tcgc	ccttgc	ggc	agtcac	ccc	acaaatg	cag	acaaat	ttgt	cttggga	3300
	cat	catgctg	tat	caaatg	cac	caaagta	aac	acactca	ctg	agagagg	agta	gaagtt	3360
25	gtca	atgcaa	cgga	aacagt	ggag	cgggaca	aac	atcccca	aaat	ttgctc	aaa	agggaaa	3420
	aga	accactg	atct	tggcca	atgc	ggactg	ttag	gggacca	ttac	cgacc	acct	caatgc	3480
	gacca	atttc	taga	atttt	agct	gatcta	ata	atcgaga	gac	gagaagg	aat	gatggt	3540
	tgtt	accgcg	gga	agtttgt	taat	gaagag	gcatt	gcgac	aaat	cctcag	agg	atcagg	3600
	ggg	attgaca	aaga	aaacaat	ggg	attcaca	tat	agtggaa	taag	gacca	cgga	acaact	3660
30	agt	gcatgta	gaag	atcagg	gtct	tcattc	tat	gcagaaa	tgg	agtggct	cct	gtcaaat	3720
	acag	acaatg	ctt	ctttccc	acaa	atgaca	aat	catata	aaa	acacagg	gag	agaatca	3780
	gct	ctgatag	tct	ggggaat	ccac	cattca	ggat	caacca	ccga	acagac	caa	actatat	3840
	ggg	agtggaa	ataa	aactgat	aac	agtcggg	ag	ttccaaat	at	catcaatc	ttt	gtgccc	3900
	agt	ccaggaa	cacg	accgca	gata	aatggc	cgt	tcggac	ggat	tgattt	tcatt	gggtg	3960
35	atct	tggatc	cca	atgatac	ag	ttactttt	ag	tttcaatg	ggg	ctttcat	ag	ctccaaat	4020
	cgt	gccagct	tct	ttagggg	aa	agtcctatg	ggg	atccaga	gcg	atgtgca	gg	ttgatgct	4080
	aatt	gcgaag	ggga	atgcta	cc	acagtggga	ggg	actataa	ca	agcagatt	gc	cttttcaa	4140
	aac	ataaata	gcag	agcagt	tgg	caaatgc	cca	agatatg	taaa	acagga	aag	tttatta	4200
	ttgg	caactg	ggat	gaagaa	cg	ttcccga	cct	tccaaaa	aa	aggaaaaa	aag	aggcctg	4260
40	ttt	ggtgcta	tag	caggggt	tatt	gaaaat	ggt	tgggaag	gtc	tggtcga	cgg	gtggtac	4320
	ggt	ttcaggc	atc	agaatgc	aca	aggagaa	gga	actgcag	cag	actacaa	aag	cacccaa	4380
	tcgg	caattg	atc	agataac	cgg	aaagtta	aat	agactca	tta	agaaaac	ca	accagcaa	4440
	ttt	gagctaa	tag	ataatga	att	cactgaa	gtg	gaaaagc	ag	attggcaa	ttt	aattaac	4500
	tgg	accaaag	act	ccatcac	aga	agtatgg	tct	tacaatg	ctg	aacttct	tgt	ggcaatg	4560
45	gaaa	accagc	acac	tattga	ttt	ggctgat	tcag	agatga	aca	agctgta	tgag	cagtg	4620
	agga	acaat	taag	ggaaaa	tg	ctgaagag	gat	ggcactg	gtt	gctttga	aatt	tttcat	4680
	aaat	gtgacg	atg	attgtat	gg	ctagtata	agga	acaata	ctt	atgatca	cag	caaatac	4740
	agaga	agaag	cgat	gcaaaa	taga	atacaa	att	gaccag	tcaa	attgag	tag	tggctac	4800
	aaag	atgtga	tact	ttgggt	tag	cttcggg	gc	atcatgct	ttt	tgttct	tg	cattgca	4860
50	atgg	gccttg	tttt	catatg	tgt	gaagaac	gga	aacatgc	ggt	gcactat	atg	catttaa	4920
	agct	tgc	atg										4930

<210> 2

<211> 5811

<212> DNA

<213> Influenza virus

EP 1 035 209 A1

<400> 2
5 aattccttttg cctaatttta atgaggactt aacctgtgga aatatttttga tgtgggaagc 60
tgttactgtt aaaactgagg ttattgggggt aactgctatg ttaaacttgc attcaggggac 120
acaaaaaact catgaaaatg gtgctggaaa acccattcaa ggggtcaaatt ttcattttttt 180
tgctgttgggt ggggaacctt tggagctgca ggggtgtgta gcaaactaca ggaccaaata 240
tcctgctcaa actgtaaccc caaaaaatgc tacagttgac agtcagcaga tgaactactga 300
ccacaaggct gttttggata aggataatgc ttatccagtg gagtgctggg ttcctgatcc 360
10 aagtaaaaaat gaaaaacta gatatttttg aacctacaca ggtggggaaa atgtgcctcc 420
tgttttgcac attactaaca cagcaaccac agtgcttctt gatgagcagg gtgttgggcc 480
cttgtgcaaa gctgacagct tgtatgtttc tgtgttgac atttgtgggc tgtttacca 540
cacttctgga acacagcagt ggaagggact tcccagatat tttaaaatta ccttagaaa 600
gcggtctgtg aaaaacccct acccaatttc ctttttgtta agtgacctaa ttaacaggag 660
15 gacacagagg gtggatgggc agcctatgat tggatgtcc tctcaagtag aggagggttag 720
ggtttatgag gacacagagg agcttctctg ggatccagac atgataagat acattgatga 780
gtttggacaa accacaacta gaatgcagt aaaaaaatgc tttatttgtg aaatttgtga 840
tgctattgct ttatttghta ccattataag ctgcaataaa caagttaaca acaacaattg 900
cattcattttt atgtttcagg ttcaggggga ggtgtgggag gttttttaaa gcaagtaaaa 960
20 cctctacaaa tgtggtatgg ctgattatga tctctagtca aggcactata catcaaatat 1020
tccttattaa cccctttaca aattaaaaag ctaaaggtag acaatttttg agcatagtta 1080
ttaatagcag acactctatg cctgtgtgga gtaagaaaaa acagtatgtt atgattataa 1140
ctgttatgcc tacttataaa ggttacagaa tatttttcca taattttctt gtatagcagt 1200
gcagcttttt cctttgtggt gtaaatagca aagcaagcaa gagttctatt actaaacaca 1260
25 gcatgactca aaaaacttag caattctgaa ggaaagtcc tggggctctc tacctttctc 1320
ttcttttttg gaggagtaga atgttgagag tcagcagtag cctcatcatc actagatggc 1380
atcttctctg agcaaacag gttttctca ttaaaggcat tccaccactg ctcccattca 1440
tcagttccat aggttggat ctaaaataca caaacaatta gaatcagtag tttaacacat 1500
tatacactta aaaattttat atttacctta gagctttaaa tctctgtagg tagtttgtcc 1560
30 aattatgtca caccacagaa gtaaggttcc ttcacaaaga tccgggacca aagcggccat 1620
cgtgcctccc cactcctgca gttcgggggc atggatgcgc ggatagccgc tgcgtggttc 1680
ctggatgccg acggaatttc actgccggta gaactccgcg aggtcgtcca gcctcaggca 1740
gcagctgaac caactcgcga ggggatcgag cccgggggtg gcgaagaact ccagcatagc 1800
atccccgcgc tggaggatca tccagccggc gtcccggaaa acgattccga agcccaacct 1860
35 ttcatagaag ggcgcgtggt aatcgaaatc tctgtatggc aggttgggcg tcgcttggtc 1920
ggtcatttcg atgaattcga gctcggatcc cggggatcct ctagaggcat ttcagtttcg 1980
tcctcacgga ctcatcagag ttgctcaatt cgaacccag agtcccgtc agaagaactc 2040
gtcaagaagg cgatagaagg cgatgcgctg cgaatcgga gcggcgatac cgtaaaagc 2100
gaggaagcgg tcagccatt cgccgccaag ctcttcagca atatcacggg tagccaacgc 2160
tatgtcctga tagcgttccg ccacacccag ccggccacag tcgatgaatc cagaaaagcg 2220
40 gccattttcc accatgatat tcggcaagca ggcacgcga tgggtcacga cgagatcctc 2280
gccgtcgggc atgcgcgcct tgagcctggc gaacagttcg gctggcgca gccctgatg 2340
ctcttcgtcc agatcatcct gatcgacaag accggtcttc atccgagtac gtgctcgctc 2400
gatgcgatgt ttcgcttggg ggtcgaatgg gcaggtagcc ggatcaagcg tatgcagccg 2460
45 ccgcattgca tcagccatga tggatacttt cctggcagga gcaaggtgag atgacaggag 2520
atcctgcccc ggcacttcgc ccaatagcag ccagtcctt cccgcttcag tgacaacgct 2580
gagcacagct gcgcaaggaa cgcccgctcg gccagccac gatagccgcg ctgcctcgtc 2640
ctgcagttca ttcagggcac cggacaggct ggtcttgaca aaaagaaccg ggcgccccctg 2700
cgctgacagc cggaacacgg cggcatcaga gcagccgatt gtctgttgtg cccagtcata 2760
gccgaatagc ctctccaccc aagcggcccg agaacctgcg tgcaatccat cttgttcaat 2820
50 catgcgaaac gatcctcatc ctgtctcttg atcagatctt gatccccctg gccatcagat 2880
ccttggcggc aagaaaagcca tccagtttac tttgcagggc tcccaacct taccagaggg 2940
cgccccagct ggcaattccg gttcgttgc tgtccataaa accgcccagt ctagctatcg 3000
ccatgtaagc ccactgcaag ctacctgctt tctctttgcg cttgcgtttt cccttgcca 3060
gatagcccag tagctgacat tcatccgggg tcagcaccgt ttctgcggac tggctttcta 3120
55 cgtgttccgc ttccttttag agcccttgcg ccctgagtgc ttgcggcagc gtgaagcttt 3180

EP 1 035 209 A1

	ttgcaaaagc	ctaggcctcc	aaaaaagcct	cctcactact	tctggaatag	ctcagaggcc	3240
	gaggcggcct	cggcctctgc	ataaataaaa	aaaattagtc	agccatgggg	cggagaatgg	3300
	gcggaactgg	gcggagttag	gggcgggatg	ggcggagtta	ggggcgggac	tatggttgct	3360
5	gactaattga	gatgcatgct	ttgcatactt	ctgcctgctg	gggagcctgg	ggactttcca	3420
	cacctggttg	ctgactaatt	gagatgcatg	ctttgcatac	ttctgcctgc	tggggagcct	3480
	ggggactttc	cacaccctaa	ctgacacaca	ttccacagct	gcctcgcgcg	tttcggtgat	3540
	gacggtgaaa	acctctgaca	catgcagctc	ccggagacgg	tcacagcttg	tctgtaagcg	3600
	gatgccggga	gcagacaagc	ccgtcagggc	gcgtcagcgg	gtgttgggcg	gtgtcggggc	3660
10	gcagccatga	cccagtcacg	tagcgatagc	ggagtgtata	ctggcttaac	tatgcggcat	3720
	cagagcagat	tgtactgaga	gtgcaccata	tgcggtgtga	aataccgcac	agatgcgtaa	3780
	ggagaaaata	ccgcacacgg	cgtcttccg	cttctcgtct	cactgactcg	ctgcgtcgg	3840
	tcgttcggct	gcggcgagcg	gtatcagctc	actcaaaagg	ggtaatacgg	ttatccacag	3900
	aatcagggga	taacgcagga	aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaacc	3960
15	gtaaaaaggc	cgcgttgctg	gcgtttttcc	ataggctccg	ccccctgac	gagcatcaca	4020
	aaaatcgacg	ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	4080
	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctgccgctt	accggatacc	4140
	tgtccgcctt	tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggtatc	4200
	tcagttcggg	gtaggtcggt	cgtcccaagc	tgggctgtgt	gcacgaaccc	cccgttcagc	4260
20	ccgaccgctg	cgccttatcc	ggtaactatc	gtcttgagtc	caacccggtg	agacacgact	4320
	tatcgccact	ggcagcagcc	actggtaaca	ggattagcag	agcgaggtag	gtaggcgggtg	4380
	ctacagagtt	cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	gtatttggta	4440
	tctgcgctct	gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	tgatccggca	4500
	aacaaaccac	cgtctggtagc	gggtggtttt	ttgtttgcaa	gcagcagatt	acgcgcagaa	4560
25	aaaaaggatc	tcaagaagat	cctttgatct	tttctacggg	gtctgacgct	cagtggaaacg	4620
	aaaactcacg	ttaagggtat	ttgggtcatg	gattatcaaa	aaggatcttc	acctagatcc	4680
	ttttaaatta	aaaatgaagt	tttaaataca	tctaaagtat	atatgagtaa	acttgggtctg	4740
	acagttacca	atgcttaatc	agtgaggcac	ctatctcagc	gatctgtcta	tttcggtcat	4800
	ccatagttgc	ctgactcccc	gtcgtgtaga	taactacgat	acgggagggc	ttaccatctg	4860
30	gccccagtgc	tgcaatgata	ccgcgagacc	cacgctcacc	ggctccagat	ttatcagcaa	4920
	taaaccagcc	agccggaagg	gccgagcgca	gaagtgggtc	tgcaacttta	tccgcctcca	4980
	tccagtctat	taattgttgc	cgggaagcta	gagtaagtag	ttcgccagtt	aatagtttgc	5040
	gcaacgttgt	tgccattgct	gcaggcatcg	tgggtgtcacg	ctcgtcgttt	ggtatggctt	5100
	cattcagctc	cgtttcccaa	cgatcaaggc	gagttacatg	atcccccatg	ttgtgcaaaa	5160
35	aagcggttag	ctccttcggg	cctccgatcg	ttgtcagaag	taagttggcc	gcagtgttat	5220
	cactcatggt	tatggcagca	ctgcataatt	ctcttactgt	catgccatcc	gtaagatgct	5280
	tttctgtgac	tgggtgagtac	tcaaccaagt	cattctgaga	atagtgtatg	cggcgaccga	5340
	gttgctcttg	cccggcgctc	acacgggata	ataccgcgcc	acatagcaga	actttaaaag	5400
	tgctcatcat	tggaaaacgt	tcttcggggc	gaaaactctc	aaggatctta	ccgctgttga	5460
40	gatccagttc	gatgtaaccc	actcgtgcac	ccaactgatc	ttcagcatct	tttactttca	5520
	ccagcgtttc	tgggtgagca	aaaacaggaa	ggcaaaatgc	cgcaaaaaag	ggaataaggg	5580
	cgacacggaa	atgttgtaata	ctcatactct	tccctttttca	atattattga	agcatttatc	5640
	agggttattg	tctcatgagc	ggatacatat	ttgaatgtat	ttagaaaaat	aaacaaatag	5700
	gggttcgcg	cacatttccc	cgaaaagtgc	cacctgacgt	ctaagaaacc	attattatca	5760
45	tgacattaac	ctataaaaaat	aggcgtatca	cgaggccctt	tcgtcttcaa	g	5811
	<210>	3					
	<211>	2005					
	<212>	DNA					
	<213>	Influenza virus					
50	<400>	3					
	agtagaaaca	agggtatttt	tctttaccta	gctaggcctg	cgcgcaatta	accctcacta	60
	aagggaaaca	aagctggagc	tccaccgcgg	tggcggccgc	tctagcatat	gttttttcgtc	120
	tcagccaatc	cctctagcat	atgtttttcg	tctcagccaa	tccctctaga	agcttcgtac	180
55	gcatgcaagc	ttttaaatag	tatagtgcac	cgcagtgttc	cgttcttcac	acatatgaaa	240

EP 1 035 209 A1

	acaaggccca	ttgcaatggc	aagaagcaaa	aagcatgatg	ccccgaagct	aaaccaaagt	300
	atcacatctt	tgtagccact	actcaatttg	actgggtcaa	tttgtattct	attttgcata	360
	gcttcttctc	tgtatttgct	gtgatcataa	gtattgttcc	ttatactagc	catacaatca	420
5	tcgtcacatt	tatgaaaaat	ttcaaagcaa	ccagtgccat	cctcttcagc	attttccctt	480
	aattgtttcc	tcaactcgct	atacagcttg	ttcatctctg	aatcagccaa	atcaatagtg	540
	tgctgggttt	ccattgccac	aagaagttca	gcattgtaag	accatacttc	tgtgatggag	600
	tctttgggtc	agttaattaa	attgccaatc	tgcttttcca	cttcagtga	ttcattatct	660
	attagctcaa	attgctgggt	ggttttctta	atgagtctat	ttaaactttc	ggttatctga	720
10	tcaattgccg	attgggtgct	tttgtagtct	gctgcagttc	cttctccttg	tgcattctga	780
	tgctgaaac	cgtaccaccc	gtcgaccaga	ccttccaac	cattttcaat	aaacctgct	840
	atagcaccaa	acaggcctct	tttttccctt	tttttggaag	gttcgggaac	gttcttcate	900
	ccagttgcca	ataataaact	ttcctgtttt	acatatcttg	ggcatttgcc	aactgctctg	960
	ctatttatgt	tttgaaaagg	caatctgctt	gttatagtc	ctccactgtg	gtagcattcc	1020
15	ccttcgcaat	tagcatcaac	ctgcacatcg	ctctggatcc	ccatggactt	tcccccaag	1080
	aagctggcac	gatttggagc	tatgaaagcc	ccattgaaac	taaaagtaac	tgtatcattg	1140
	ggatccaaga	tcaaccaatg	aaaatcaatc	cgtccggacc	ggccatttat	ctgcggtcgt	1200
	gttcctggac	tcggcacaaa	agattgatga	tatttggaa	tcccgaactg	tatcagttta	1260
	tttccactcc	catatagttt	ggctctgttc	gtggttgatc	ctgaatgggt	gattccccag	1320
20	actatcagag	ctgattctct	ccctgtgttt	ttgtatgatt	ttgtcatttg	tgggaaagaa	1380
	gcattgtctg	tatttgacag	gagccactcc	atttctgcat	agaatgaaga	ccctgatctt	1440
	ctacatgcac	tagttgttcc	gttggtcctt	attccactat	atgtgaatcc	cattgtttct	1500
	ttgtcaatcc	cactgatcc	tctgaggatt	tgtcgcaatg	cctcttcatt	aacaaacttc	1560
	cccgggtaac	aaacatcatt	tccttctcgt	ctctcgatta	ttagatcagc	tgaaaattct	1620
25	agaaattggg	cgcattgagg	tggtccggta	atggtcccta	acagtccgca	ttggccaaga	1680
	tcagtgggtc	ttttcccttt	tgagcaaat	ttggggatgt	ttgtccgctc	cactgtttcc	1740
	gttgcatgta	caacttctac	tcctctctca	gtgagtgtgt	ttactttggg	gccatttgat	1800
	acagcatgat	gtccaagaca	aattttgtct	gcatttgggg	ggatgactgc	cgcaagggcg	1860
	aaaaccagga	tttgagtgtt	cattttgggt	cctacaatat	gtttttcgtc	tcagccaatc	1920
30	cctggtacaa	tatgtttttc	gtctcagcca	atcctggtac	gatgtggatg	tcactcagtg	1980
	agtgattatc	tacctgctt	ttgct				2005

<210> 4

<211> 1146

<212> DNA

35 <213> Influenza virus

<400> 4

	agtagaaaca	agggtathtt	tctttaccta	gctaggcctg	cgcgcaatta	accctcacta	60
40	aagggaaaca	aagctggagc	tccaccgcgg	tggcgccgcg	tctagcatat	gtttttctgt	120
	tcagccaatc	cctctagcat	atgtttttct	tctcagccaa	tccctctaga	agcttcgtac	180
	gcattgctta	ataagctgaa	acgagaaagt	tcttatctct	tgctccactt	caagcggtag	240
	ttgtaaggct	tgcataaatg	ttatttgttc	aaaactattc	tctgttatct	tcaatctatg	300
	tctcacttct	tcaattaaac	atcttatttc	ttcaaatttc	tgactcaatt	gttctcgcca	360
	ttttccgttt	ctgctttgga	gggagtgagg	gtcccccatt	ctcattactg	cttctccaag	420
45	cgaatctctg	tatagtttca	gagactcgaa	ctgtgttata	attccattca	agtcctccga	480
	tgaggacccc	aattgcattt	ttgacatcct	catcagtatg	tcctggaaga	gaaggcaatg	540
	gtgaaatttc	gccgacaatt	gtccctccat	cgggttaaagc	ccttaatagt	atgagagttt	600
	ccagccgata	gaaaatcaca	ctgaagtttg	cttccagtat	gatgttcttc	cccatgatcg	660
50	cctgggtccat	tctgatgcaa	agggagcctg	ccactttctg	tttgggcatg	agcatgaacc	720
	agtcccttga	catctcttca	agagtcattg	cagttaggta	gcgtgtagca	ggtacagagg	780
	caatgggtcat	tttaagtgcc	tcatcggatt	cgtcctccag	aatccgctcc	actatctgct	840
	ttccaacacg	agtagctgtg	tcgatgtcca	gaccaagagt	gctgcctctt	ccccccaggg	900
	acttctgata	tcggcggaag	cgggtcaagga	atggggcatc	acccatttct	tgggtctgca	960
	atcgtttgcg	gacatgccaa	agaaagcagt	ctacctgaaa	gcttgacaca	gtgttggaat	1020
55	ccattatggg	acctacaata	tgtttttcgt	ctcagccaat	ccctggtaca	atatgttttt	1080

EP 1 035 209 A1

cgtctcagcc aatcctggta cgatgtggat gtcactcagt gagtgattat ctaccctgct 1140
tttgct 1146

<210> 5

<211> 5860

<212> DNA

<213> Influenza virus

<400> 5

10	catcgattgg	ctgactgatg	agtccgtgag	gacgaaacga	aaaacatatt	gtagagctcg	60
	aattcatcga	aatgaccgac	caagcgacgc	ccaacctgcc	atcacgagat	ttcgattcca	120
	ccgccgcctt	ctatgaaagg	ttgggcttcg	gaatcgtttt	ccgggacgcc	ggctggatga	180
	tectccagcg	cggggatctc	atgctggagt	tcttcgcccc	ccccgggctc	gatccccctg	240
	cgagttgggt	cagctgctgc	ctgaggctgg	acgacctcgc	ggagttctac	cggcagtgca	300
15	aatccgtcgg	catccaggaa	accagcagcg	gctatccgcg	catccatgcc	cccgaactgc	360
	aggagtgggg	aggcacgatg	gccgctttgg	tcccggatct	ttgtgaagga	accttacttc	420
	tgtgggtgtga	cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaataata	480
	aaatttttaa	gtgtataatg	tgtaaacta	ctgattctaa	ttgtttgtgt	attttagatt	540
	ccaacctatg	gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	600
20	ttttgctcag	aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	660
	actcctccaa	aaaagaagag	aaaggtagaa	gacccaagg	actttccttc	agaattgcta	720
	agttttttga	gtcatgctgt	gtttagtaat	agaactcttg	cttgctttgc	tatttacacc	780
	acaaaggaaa	aagctgcact	gctatacaag	aaaattatgg	aaaaatattc	tgtaaccttt	840
	ataagtaggc	ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	900
25	agagtgtctg	ctattaataa	ctatgctcaa	aaattgtgta	ccttttagctt	tttaatttgt	960
	aaaggggtta	ataaggaata	tttgatgtat	agtgccttga	ctagagatca	taatcagcca	1020
	taccacattt	gtagaggttt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	1080
	gaaacataaa	atgaatgcaa	ttgttggtgt	taacttggtt	attgcagctt	ataatgggtta	1140
	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcattctag	1200
30	ttgtgggttg	tccaaactca	tcaatgtatc	ttatcatgtc	tggatcccc	ggaagctcct	1260
	ctgtgtcctc	ataaacctca	acctcctcta	cttgagagga	cattccaatc	ataggctgcc	1320
	catccaccct	ctgtgtcctc	ctgttaatta	ggctacttaa	caaaaaggaa	attgggtagg	1380
	ggtttttcac	agaccgcttt	ctaagggtaa	ttttaaaata	tctgggaagt	cccttccact	1440
	gctgtgttcc	agaagtgttg	gtaaacagcc	cacaaatgtc	aacagcagaa	acatacaagc	1500
35	tgtcagcttt	gcacaagggc	ccaacacctt	gctcatcaag	aagcactgtg	gttgctgtgt	1560
	tagtaatgtg	caaaacagga	ggcacatttt	ccccacctgt	gtaggttcca	aaatatctag	1620
	tgttttccatt	tttacttgga	tcaggaaccc	agcactccac	tggataagca	ttatccttat	1680
	ccaaaacagc	cttggtgtca	gtgttcatct	gctgactgtc	aactgtagca	ttttttgggg	1740
	ttacagtttg	agcaggatat	ttgggtcctgt	agtttgctaa	cacacctgtc	agctccaaaag	1800
40	gttccccacc	aacagcaaaa	aaatgaaaaat	ttgaccttg	aatgggtttt	ccagcaccat	1860
	tttcatgagt	tttttgtgtc	cctgaatgca	agttaaact	agcagttacc	ccaataacct	1920
	cagttttaac	agtaacagct	tcccacatca	aaatatctcc	acaggttaag	tcctcattta	1980
	aataggcaa	aggaattctt	gaagacgaaa	gggcctcgtg	atacgccat	ttttataggt	2040
	taatgtcatg	ataataatgg	tttcttagac	gtcaggtggc	acttttcggg	gaaatgtgctg	2100
45	cggaaccctt	atgtgtttat	ttttctaaat	acattcaaat	atgtatccgc	tcatgagaca	2160
	ataaccctga	taaatgcttc	aataatattg	aaaaagggaag	agtatgagta	ttcaacattt	2220
	ccgtgtcgcc	cttattccct	tttttgcggc	attttgcctt	cctgtttttg	ctcaccacaga	2280
	aacgctgggtg	aaagtaaaaag	atgctgaaga	tcagttgggt	gcacgagtgg	gttacatcga	2340
	actggatctc	aacagcggta	agatccttga	gagttttcgc	cccgaagaac	gttttccaat	2400
50	gatgagcact	tttaaagttc	tgctatgtgg	cgcggtatta	tcccgtgttg	acgccgggca	2460
	agagcaactc	ggtcgccgca	tacactattc	tcagaatgac	ttggttgagt	actcaccagt	2520
	cacagaaaag	catcttacgg	atggcatgac	agtaagagaa	ttatgcagtg	ctgccataac	2580
	catgagtgat	aacactgcgg	ccaacttact	tctgacaacg	atcggaggac	cgaaggagct	2640
	aaccgctttt	ttgcacaaca	tgggggatca	tgtaactcgc	cttgatcggt	gggaaccgga	2700
55	gctgaatgaa	gccataccaa	acgacgagcg	tgacaccacg	atgcctgcag	caatggcaac	2760

EP 1 035 209 A1

	aacgttg	gcgc	aaactatta	ctggcgaact	acttactcta	gcttcccgc	aacaattaat	2820	
	agactgg	atg	gaggcg	gata	aagttgcagg	accacttctg	cgctcggccc	ttccggctgg	2880
	ctgggtt	tatt	gctgata	aat	ctggagccg	tgagcgtggg	tctcgcggta	tcattgcagc	2940
	actgggg	cca	gatggta	aagc	cctcccgtat	cgtagttatc	tacacgacgg	ggagtcaggc	3000
5	aactatg	gat	gaacgaa	ata	gacagatcgc	tgagataggt	gcctcactga	ttaagcattg	3060
	gtaactg	tca	gaccaag	ttt	actcatatat	acttttagatt	gatttaaaac	ttcattttta	3120
	atttaaa	agg	atctagg	tga	agatcctttt	tgataatctc	atgacccaaa	tcccttaacg	3180
	tgagttt	tctg	ttccact	gag	cgtcagaccc	cgtagaaaag	atcaaaggat	cttcttgaga	3240
	tcctttt	ttt	ctgcg	cgtaa	tctgctgctt	gcaaacaaaa	aaaccaccgc	taccagcggt	3300
10	ggtttg	tttg	ccgatca	aag	agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	3360
	agcgca	gata	caaatac	tg	tccttctagt	gtagccgtag	ttaggccacc	acttcaagaa	3420
	ctctgt	tagca	ccgcct	acat	acctcgctct	gctaatacctg	ttaccagtgg	ctgctgccag	3480
	tggcg	ataag	tcgtgt	ctta	ccgggttgga	ctcaagacga	tagttaccgg	ataaggcgca	3540
	gcggtc	ggggc	tgaac	ggggg	gttcgtgcac	acagcccagc	ttggagcgaa	cgacctacac	3600
15	cgaact	gaga	tacct	acagc	gtgagctatg	agaaagcgcc	acgcttcccg	aaggagaaaa	3660
	ggcgg	acagg	tatcc	ggtaa	gcggcaggg	cggaacagga	gagcgacga	gggagcttcc	3720
	aggggg	aaaac	gcctg	gtatc	tttatagtcc	tgtcgggttt	cgccacctct	gacttgagcg	3780
	tcgatt	ttttg	tgatg	ctcgt	cagggggggc	gagcctatgg	aaaaacgcca	gcaacgcggc	3840
	cttttt	acgg	ttcct	ggcct	tttgctggcc	ttttgctcac	atgttctttc	ctgcggtatc	3900
20	ccctg	attct	gtggata	aacc	gtattaccgc	ctttgagtga	gctgataccg	ctcgccgcag	3960
	ccgaac	gacc	gagcg	cagcg	agtcagtgag	cgaggaagcg	gaagagcgcc	tgatgcggta	4020
	ttttct	cctt	acgc	atctgt	gcggtatttc	acacgcgata	tggtgcactc	tcagtacaat	4080
	ctgct	ctgat	ccgc	catagt	taagccagta	tacactccgc	tatcgctacg	tgactgggtc	4140
	atggc	tgcgc	ccgc	acaccc	gccaacaccc	gctgacgcgc	cctgacgggc	ttgtctgctc	4200
25	ccggc	atccg	cttac	agaca	agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	4260
	tcaccg	tcat	caccg	aaacg	cgcgaggcag	ctgtggaatg	tgtgtcagtt	aggggtgtgga	4320
	aagtc	ccccag	gctccc	acgc	aggcagaagt	atgcaaagca	tgcatctcaa	ttagtcagca	4380
	accagg	tgtg	gaaagt	cccc	aggctcccca	gcaggcagaa	gtatgcaaag	catgcatctc	4440
	aattag	tcatg	caacc	atagt	cccgccccct	actccgcccc	tcccggcccc	aactccgccc	4500
30	agttcc	gccc	attct	ccgcc	ccatggctga	ctaatttttt	ttattttatg	agaggccgag	4560
	gccgc	ctcgg	cctct	gagct	attccagaag	tagtgaggag	gcttttttgg	aggcctaggc	4620
	ttttg	caaaa	agctt	cacgc	tgccgcaagc	actcaggggc	caagggctgc	taaaggaagc	4680
	ggaa	cacgta	gaaag	ccagt	ccgcagaaac	ggtgctgacc	ccggatgaat	gtcagctact	4740
	gggct	atctg	gaca	agggaa	aacgcaagcg	caaagagaaa	gcaggtagct	tgcagtgggc	4800
35	ttacat	ggcg	atagc	tagac	tggggcggtt	tatggacagc	aagcgaaccg	gaattgccag	4860
	ctgggg	cgcc	ctctg	gtaag	gttgggaagc	cctgcaaagt	aaactggatg	gctttcttgc	4920
	cgcca	aggat	ctgat	ggcg	aggggatcaa	gatctgatca	agagacagga	tgaggatcgt	4980
	ttcg	catgat	tga	acaagat	ggattgcacg	cagggttctcc	ggccgcttgg	gtggagaggc	5040
	tattc	ggcta	tgact	gggca	caacagacaa	tcgggtgctc	tgatgccgcc	gtgttccggc	5100
40	tgtc	agcgca	ggggc	gccccg	gttctttttg	tcaagaccga	cctgtccggg	gccctgaatg	5160
	aactg	cagga	cgagg	cagcg	cggtatcgt	ggctggccac	gacgggcgtt	ccttgcgag	5220
	ctgtg	ctcga	cgttg	tcact	gaagcgggaa	gggactggct	gctattgggc	gaagtgccgg	5280
	ggc	aggatct	cctgt	catct	caccttgctc	ctgccgagaa	agtatccatc	atggctgatg	5340
	caatg	cgggc	gctgc	atacgc	cttgatccgc	ctacctgccc	attcgaccac	caagcgaaac	5400
45	atcg	catcga	gcg	agcacgt	actcgatgg	aagccgggtc	tgctgatcag	gatgatctgg	5460
	acga	agagca	tcagg	gggtc	gcgccagccg	aactgttcgc	caggctcaag	gcgcgcacgc	5520
	ccg	acggcg	gga	ctctcgtc	gtgacccatg	gcgatgcctg	cttgccgaat	atcatggtgg	5580
	aaa	atggccg	ctttt	ctgga	ttcatcgact	gtggccggct	gggtgtggcg	gaccgctatc	5640
	agg	acatagc	gtt	ggctacc	cgtgatattg	ctgaagagct	tggcggcgaa	tgggctgacc	5700
50	gcttc	ctcgt	gctt	tacgg	atcgccgctc	ccgattcgca	gcgcacgcgc	ttctatcgcc	5760
	ttctt	gacga	gtt	cttctga	gcgggactct	ggggttcgaa	tcctaccagg	gattggctga	5820
	ctgat	gagtc	cgt	gaggacg	aaacgaaaaa	catatggtac			5860
	<210>	6							
55	<211>	4610							

EP 1 035 209 A1

<212> DNA

<213> Influenza virus

<400> 6

5	gaggcatttc	agtcagttgc	tcaaggtacc	aaaatgaaca	ctcaaatect	ggttttcgcc	60
	cttgcggcag	tcacccccac	aaatgcagac	aaaatttgtc	ttggacatca	tgctgtatca	120
	aatggcacca	aagtaaacac	actcactgag	agaggagtag	aagttgtcaa	tgcaacggaa	180
	acagtggagc	ggacaaacat	ccccaaaat	tgctcaaaag	ggaaaagaac	cactgatctt	240
	ggccaatgcg	gactgttagg	gaccattacc	ggaccacctc	aatgcgacca	atttctagaa	300
10	ttttcagctg	atctaataat	cgagagacga	gaaggaaatg	atgtttgtta	cccggggaag	360
	tttggttaatg	aagaggcatt	gcgacaaatc	ctcagaggat	caggtgggat	tgacaaagaa	420
	acaatgggat	tcacatatag	tggaataagg	accaacggaa	caactagtgc	atgtagaaga	480
	tcagggtctt	cattctatgc	agaaatggag	tggtcctctg	caaatacaga	caatgcttct	540
	ttcccacaaa	tgacaaaatc	atacaaaaac	acagggagag	aatcagctct	gatagtctgg	600
15	ggaatccacc	attcaggatc	aaccaccgaa	cagaccaaac	tatatgggag	tggaataaaa	660
	ctgataacag	tcgggagttc	caaatatcat	caatcttttg	tgccgagtc	aggaacacga	720
	ccgcagataa	atggccgggtc	cggaaggatt	gatttttcatt	ggttgatctt	ggatcccaat	780
	gatacagtta	cttttagttt	caatggggct	ttcatagctc	caaactcgtgc	cagcttcttg	840
	aggggaaagt	ccatggggat	ccagagcgat	gtgcaggttg	atgctaattg	cgaaggggaa	900
20	tgctaccaca	gtggagggac	tataacaagc	agattgcctt	ttcaaaacat	aaatagcaga	960
	gcagttggca	aatgcccaag	atatgtaaaa	caggaaagtt	tattattggc	aactgggatg	1020
	aagaacgttc	ccgaaccttc	caaaaaaagg	aaaaaaagag	gcctgtttgg	tgctatagca	1080
	gggtttattg	aaaatggttg	ggaaggtctg	gtcgacgggt	ggtacggttt	caggcatcag	1140
	aatgcacaag	gagaaggaac	tgacgcagac	tacaaaagca	cccaatcggc	aattgatcag	1200
25	ataaccggaa	agttaaatag	actcattaag	aaaaccaacc	agcaatttga	gctaatagat	1260
	aatgaattca	ctgaagtggg	aaagcagatt	ggcaatttaa	ttaactggac	caaagactcc	1320
	atcacagaag	tatggtctta	caatgctgaa	cttcttggg	caatggaaaa	ccagcacact	1380
	attgatattg	ctgattcaga	gatgaacaag	ctgtatgagc	gagtgaggaa	acaattaaag	1440
	gaaaatgctg	aagaggatgg	cactgggtgc	tttgaaattt	ttcataaatg	tgacgatgat	1500
30	tgatgggcta	gtataaggaa	caatacttat	gatcacagca	aatacacaga	agaagcgatg	1560
	caaaatagaa	gtataaggaa	cccagtcaaa	ttgagttagt	gctacaaaga	tgtgatactt	1620
	tggttttagct	tcggggcatc	atgctttttg	cttcttgcca	ttgcaatggg	ccttgttttc	1680
	atatgtgtga	agaacggaaa	catgcggtgc	actatttgta	tataggtttg	gaaaaaaaca	1740
	ccccttgttt	ctactcccc	ccaacttcgg	aggtcgacca	gtactccggg	cgaaactttg	1800
35	tttttttttt	ttccccgat	gctggaggtc	gaccagatgt	ccgaaagtgt	cccccccccc	1860
	cccccccccc	ggcgcggaac	ggcggggcca	ctctggactc	tttttttttt	tttttttttt	1920
	ttttttgggg	atcgcccgct	agcttctgtt	ttggcggtat	agagaagatt	ttcagcctga	1980
	tacagattaa	atcagaacgc	agaagcggtc	tgataaaaaca	gaatttgctt	ggcggcagta	2040
	gcgcgggtgg	cccacctgac	cccatgccga	actcagaagt	gaaacgccgt	agcgccgatg	2100
40	gtagtgtggg	gtctcccat	gcgagagtag	ggaactgcc	ggcatcaaat	aaaacgaaag	2160
	gctcagtcga	aagactgggc	cttctggttt	atctgttgtt	tgctgggtgaa	cgctctcctg	2220
	agtaggacaa	atccgcgggg	agcggatttg	aacgttgcca	agcaacggcc	cggagggtgg	2280
	cgggcaggac	gcccgcata	aactgccagg	catcaaatta	agcagaaggc	catcctgacg	2340
	gatggccttt	ttgcgtttct	acaaactctt	ttgtttattt	ttctaaatac	attcaaatat	2400
45	gtatccgctc	atgagacaat	aaccctgata	aatgcttcaa	taatattgaa	aaaggaagag	2460
	tatgagtatt	caacatttcc	gtgtcgccct	tattcccttt	tttgcgcat	tttgccctcc	2520
	tgtttttgct	caccagaaa	cgctggtgaa	agtaaaagat	gctgaagatc	agttgggtgc	2580
	acgagtgggt	tacatcgaac	tgatctcaa	cagcggttaag	atccttgaga	gttttcgccc	2640
	cgaagaacgt	tttccaatga	tgagcacttt	taaagtcttg	ctatgtggcg	cggtattatc	2700
50	ccgtgttgac	gcccggcaag	agcaactcgg	tcgcccata	cactattctc	agaatgactt	2760
	ggttgagtac	tcaccagtca	cagaaaagca	tcttacggat	ggcatgacag	taagagaatt	2820
	atgcagtgtc	gccataacca	tgagtataaa	cactgcggcc	aacttacttc	tgacaacgat	2880
	cggaggaccg	aaggagctaa	ccgctttttt	gcacaacatg	ggggatcatg	taactcgctt	2940
	tgatcggttg	gaaccggagc	tgaatgaagc	cataccaaac	gacgagcgtg	acaccacgat	3000
55	gcctgtagca	atggcaacaa	cgttgcgcaa	actattaact	ggcgaactac	ttactctagc	3060

EP 1 035 209 A1

```

5  ttccccgcaaa caattaatag actggatgga ggccgataaa gttgcaggac cacttctgcg 3120
   ctccggccctt ccggctggct gggtttattgc tgataaatct ggagccgggtg agcgtgggtc 3180
   tcgcgggtatc attgcagcac tggggccaga tggtaagccc tcccgatcgc tagttatcta 3240
   cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg agatagggtgc 3300
   ctcaactgatt aagcatttgg aactgtcaga ccaagtttac tcatatatac tttagattga 3360
   tttaaaactt catttttaat ttaaaaggat ctagggtgaag atcctttttg ataactctcat 3420
   gaccaaactc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaaagat 3480
   caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa 3540
   accaccgcta ccagcgggtg tttgtttgccc ggatcaagag ctaccaactc tttttccgaa 3600
10  ggtaaactggc ttcagcagag cgcagatacc aaatactgtc cttctagtgt agccgtagtt 3660
   aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt 3720
   accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata 3780
   gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agcccagctt 3840
   ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac 3900
15  gttccccgaa gggagaaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga 3960
   ggcgcagagg gagcttccag ggggaaacgc ctgggtatctt tatagtcctg tcgggttttcg 4020
   ccacctctga cttgagcgtc gattttttgt atgctcgtca ggggggaggga gcctatggaa 4080
   aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt ttgctcacat 4140
   gttctttcct gcgttatccc ctgattcatt aatgcaggtc acgatccttt ctggcgagtc 4200
20  cccgtgcgga gtcggagagc gtcctcctgag cgcgtgcggc ccgagaggtc gcgcctggcc 4260
   ggccttcggt ccctcgtgtg tcccggtcgt agggaggggccc ggccgaaaat gcttccggct 4320
   cccgctctgg agacacgggc cggcccccctg cgtgtggcac gggcgggccg gagggcgctcc 4380
   ccggcccggc gctgctcccg cgtgtgtcct ggggttgacc agagggcccc gggcgctccg 4440
   tgtgtggctg cgatggtggc gtttttgggg acaggtgtcc gtgtccgtgt cgcgcgtcgc 4500
25  ctgggcccggc ggcgtggtcg gtgacgcgac ctcccgggccc cgggggaggt atatctttcg 4560
   ctccgagtcg gcattttggg ccgcccgggtt attagtagaa acaggggtac 4610

```

<210> 7

<211> 3558

30 <212> DNA

<213> Influenza virus

<400> 7

```

35  tattagtaga aacagggtat tttttattct agtacattac gccccgccct gccactcadc 60
   gcagtactgt tgtaattcat taagcattct gccgacatgg aagccatcac agacggcatg 120
   atgaacctga atcgccagcg gcatcagcac cttgtcgcct tgcgtataat atttgcccat 180
   ggtgaaaacg ggggcgaaga agttgtccat attggccacg tttaaatcaa aactggtgaa 240
   actcaccagc ggattggctg agacgaaaaa catattctca ataaaccctt tagggaaata 300
   ggccagggtt tcaccgtaac acgccacatc ttgcgaatat atgtgtagaa actgccggaa 360
40  atcgtcgtgg tattcactcc agagcgatga aaacgtttca gtttgcctat ggaaaacggg 420
   gtaacaaggg tgaacactat cccatcacac cagctcaccg tctttcattg ccatacggaa 480
   ttccggatga gcattcatca ggcgggcaag aatgtgaata aaggccggat aaaacttgtg 540
   cttatttttc tttacggctc ttaaaaaaggc cgtaatatcc agctgaacgg tctgggtata 600
   ggtacattga gcaactgact gaaatgcctc aaaatgttct ttacgatgcc attgggatat 660
45  atcaacggtg gtatatccag tgattttttt ctccatgatt atggccatta cccttgtttc 720
   tactcccccc caacttcgga ggtcgaccag tactccgggc gaaactttgt tttttttttt 780
   tcccccgatg ctggaggctg accagatgtc cgaaagtgtc cccccccccc ccccccccg 840
   gcgcggaacg gcggggccac tctggactct tttttttttt tttttttttt tttttgggga 900
   tcggccgcta gcttctgttt tggcgatga gagaagattt tcagcctgat acagattaaa 960
50  tcagaacgca gaagcgggtc gataaaacag aatttgccctg gcggcagtag cgcggtgggtc 1020
   ccacctgacc ccattgccga ctcagaagtg aaacgccgta gcgccgatgg tagtgtggg 1080
   tctcccatg cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcaatcgaa 1140
   agactggggc tttcgtttta tctgttgtt gtcggtgaac gctctcctga gtaggacaaa 1200
   tccgcccggga gcggatttga acgttcgcaa gcaacggccc ggaggggtggc gggcaggacg 1260
55  cccgccataa actgccaggc atcaaattaa gcagaaggcc atcctgacgg atggcccttt 1320

```

EP 1 035 209 A1

	tgcgtttcta	caaactcttt	tgttttat	tctaaatata	ttcaaata	tatccgctca	1380
	tgagacaata	accctgataa	atgcttcaat	aatattgaaa	aaggaagagt	atgagtat	1440
	aacattttccg	tgctgcctt	attccctttt	ttgcggcatt	ttgccttcct	gtttttgtc	1500
5	acccagaaac	gctggtgaaa	gtaaaagatg	ctgaagatca	gttggtgca	cgagtgggt	1560
	acatcgaact	ggatctcaac	agcggtaaga	tcttgagag	tttcgcccc	gaagaacgt	1620
	ttccaatgat	gagcactttt	aaagtctgc	tatgtggcgc	ggtattatcc	cgtgttgacg	1680
	ccgggcaaga	gcaactcgg	cgccgcatac	actattctca	gaatgacttg	gttgagtact	1740
	caccagtcac	agaaaagcat	cttacggatg	gcatgacagt	aagagaatta	tgcagtgtc	1800
10	ccataaccat	gagtataaac	actgcggcca	acttacttct	gacaacgatc	ggaggaccga	1860
	aggagctaac	cgcttttttg	cacaacatgg	gggatcatgt	aactcgctt	gatcgttggg	1920
	aaccggagct	gaatgaagcc	ataccaaacg	acgagcgtga	caccacgatg	cctgtagcaa	1980
	tggaacaac	gttgcgcaaa	ctattaactg	gcgaactact	tactctagct	tcccggcaac	2040
	aattaataga	ctggatggag	gcgataaag	ttgcaggacc	acttctgcgc	tccgcccctt	2100
	cggtgtgctg	gtttattgct	gataaatctg	gagccgggtg	gcgtgggtct	cgcggtatca	2160
15	ttgcagcact	ggggccagat	ggtaagccct	cccgtatcgt	agttatctac	acgacgggga	2220
	gtcaggcaac	tatggatgaa	cgaaatagac	agatcgctga	gatagggtgc	tactgatta	2280
	agcattggta	actgtcagac	caagtttact	catatatact	ttagattgat	ttaaaacttc	2340
	atttttaatt	taaaaggatc	taggtgaaga	tcttttttga	taatctcatg	acaaaaatcc	2400
20	cttaacgtga	gttttcgctc	cactgagcgt	cagaccccg	agaaaagatc	aaaggatctt	2460
	cttgagatcc	ttttttctg	cgcgtaatct	gctgcttgca	aacaaaaaaa	ccaccgctac	2520
	cagcgtgggt	ttgtttgcgg	gatcaagagc	taccaactct	ttttccgaag	gtaactggct	2580
	tcagcagagc	gcagatacca	aatactgtcc	ttctagtgtg	gccgtagtta	ggccaccact	2640
	tcaagaactc	tgtagcaccg	cctacatacc	tcgctctgct	aatcctgtta	ccagtggctg	2700
25	ctgccagtgg	cgataagtcg	tgtcttaccg	ggttggactc	aagacgatag	ttaccggata	2760
	aggcgcagcg	gtcgggctga	acgggggggt	cgtgcacaca	gcccagcttg	gagcgaacga	2820
	cctacaccga	actgagatac	ctacagcgtg	agctatgaga	aagcgccacg	cttcccgaag	2880
	ggagaaaggc	ggacagggtat	ccggtaagcg	gcagggtcgg	aacaggagag	cgcacgaggg	2940
	agcttccagg	gggaaacgcc	tggtatcttt	atagtcctgt	cgggtttcgc	cacctctgac	3000
30	ttgagcgtcg	atttttgtga	tgctcgtcag	ggggggcgag	cctatggaaa	aacgccagca	3060
	acgggcctt	tttacgggtc	ctggcctttt	gctggccttt	tgctcacatg	ttctttcctg	3120
	cgttatcccc	tgattcatta	atgcagggtca	cgatcctttc	tggcgagtcc	ccgtgcggag	3180
	tcggagagcg	ctccctgagc	gcgtgcggcg	cgagaggctc	cgctggcccg	gccttcggct	3240
	cctcgtgtgt	cccggtcgta	ggaggggccg	gccgaaaatg	cttcgggctc	ccgctctgga	3300
35	gacacggggc	ggccccctgc	gtgtggcacg	ggcgcccg	agggcgctcc	cgccccggcg	3360
	ctgctcccg	gtgtgtcctg	gggttgacca	gagggcccg	ggcgctccgt	gtgtggctgc	3420
	gatggtggcg	tttttgggga	caggtgtccg	tgctcgtgtc	gcgcgtcgcc	tgggcccggc	3480
	gcgtggtcgg	tgacgcgacc	tcccggcccc	gggggaggtg	tatctttcgc	tccgagtcgg	3540
	cattttgggc	cgccgggt					3558
40	<210> 8						
	<211> 4343						
	<212> DNA						
	<213> Influenza virus						
45	<400> 8						
	ctttctggcg	agtccccgtg	cggagtcgga	gagcgctccc	tgagcgcgtg	cgccccgaga	60
	ggtcgcgcct	ggccggcctt	cggctccctc	tgtgtcccg	tcgtaggagg	ggccggccga	120
	aaatgcttcc	ggctcccgtc	ctggagacac	ggccggccc	cctgcgtgtg	gcacgggcgg	180
	ccgggagggc	gtccccggcc	cggcgctgct	cccgctgtg	tcttggggtt	gaccagaggg	240
50	ccccgggcgc	tccgtgtgtg	gctgcgatgg	tggcgttttt	ggggacagg	gtccgtgtcc	300
	gtgtcgcgcg	tcgctggggc	cggcggcgtg	gtcggtgacg	cgacctccc	gccccggggg	360
	aggtatatct	ttcgctccga	gtcggcattt	tgggcccggc	ggttattagt	agaaacaggg	420
	tattttttat	actagtaagc	tcgaaggagt	ccaccatgag	taaaggagaa	gaacttttca	480
	ctggagtgtg	cccaattctt	gttgaattag	atggtgatgt	taatgggcac	aaattttctg	540
55	tcagtggaga	gggtgaagg	gatgcaacat	acggaaaact	tacccttaaa	tttatttgca	600

EP 1 035 209 A1

	ctactggaaa	actacctgtt	ccatggccaa	cacttgtcac	tactttcact	tatggtgttc	660
	aatgcttttc	aagataccce	gatcatatga	aacagcatga	ctttttcaag	agtgccatgc	720
	ccgaagggtta	tgtacaggaa	agaactatat	ttttcaaaga	tgacgggaac	tacaagacac	780
5	gtgctgaagt	caagtttgaa	ggtgatcccc	ttgttaatat	aatcgagtta	aaagggtattg	840
	attttaaaga	agatggaaac	attcttggac	acaaattgga	atacaactat	aactcacaca	900
	atgtatacat	catggctgac	aagcagaaga	acggaatcaa	ggccaacttc	aagacccgcc	960
	acaacatcga	ggacggcgcc	gtgcagctgg	ccgaccacta	ccagcagaac	acccaattg	1020
	gcgatggccc	tgtcctttta	ccagacaacc	attacctgtc	cacacaatct	gcccttttga	1080
10	aagatcccaa	cgaaaagaga	gaccacatgg	tccttcttga	gtttgtaaca	gctgctggga	1140
	ttacacatgg	catggatgaa	ctatacaagg	gatcccatca	ccatcaccat	actaagctc	1200
	ctagggtctag	atatctagta	cattacgccc	cgccctgcca	ctcatcgag	tactgttcta	1260
	attcattaag	cattctgccc	acatggaagc	catcacagac	ggcatgatga	acctgaatcg	1320
	ccagcggcat	cagcaccttg	tcgccttgcc	tataatat	gcccattggt	aaaacggggg	1380
15	cgaagaagtt	gtccatattg	gccacgttta	aatcaaaact	ggtgaaactc	acccagggat	1440
	tggcactcac	aaagaacatg	ttctcgatga	atcctttagg	gaagtaggcc	aggttttcac	1500
	cgtaacacgc	cacatcttgc	gaatatatgt	gtagaaactg	ccggaaatcg	tcgtggtatt	1560
	cactccagag	cgatgaaaac	gtttcagttt	gctcatggaa	aacgggtgta	caagggtgaa	1620
	cactatccca	tatcaccagc	tcacogtctt	tcattgcca	acggaattcc	ggatgagcat	1680
20	tcacagggcg	ggcaagaatg	tgaataaagg	ccggataaaa	cttgtgctta	tttttcttta	1740
	cggctcttta	aaaggccgta	atatccagct	gaacggctctg	gttataggta	cattgagcaa	1800
	ctgactgaaa	tgccctcaaaa	tgctctttac	gatgccattg	ggatatatca	acggtggtat	1860
	atccagtgat	tttttctctc	atgattatgc	aaaaaatacc	cttgtttcta	ctcccccca	1920
	acttcggagg	tcgaccagta	ctccggcgga	aactttgttt	tttttttttc	ccccgatgct	1980
25	ggagggtcgac	cagatgtccg	aaagtgtccc	ccccccccc	ccccccggc	gcggaacggc	2040
	ggggccactc	tggactcttt	tttttttttt	tttttttttt	tttggggatc	ggccgctagc	2100
	ttctgttttg	gcggatgaga	gaagattttc	agcctgatac	agattaaatc	agaacgcaga	2160
	agcggctctga	taaaacagaa	tttgccctggc	ggcagtagcg	cgggtggtccc	acctgacccc	2220
	atgccgaact	cagaagtga	acgcgcgtagc	gccgatggta	gtgtgggggtc	tccccatgcg	2280
30	agagtaggga	actgccaggc	atcaaataaa	acgaaaggct	cagtcgaaaag	actgggcctt	2340
	tcgttttatc	tgttgtttgt	cggatgaacgc	tctctgagt	aggacaaatc	cgccgggagc	2400
	ggatttgaac	gttgcgaaagc	aacggcccg	agggtggcg	gcaggacgcc	cgccataaac	2460
	tgccaggcat	caaattaagc	agaaggccat	cctgacggat	ggcctttttg	cgtttctaca	2520
	aactcttttg	tttatttttc	taaatacatt	tccgctcatg	agacataaac	agataaac	2580
35	cctgataaat	gcttcaataa	tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	2640
	tcgcccttat	tccttttttt	gcggcatttt	gccttctgt	ttttgctcac	ccagaaacgc	2700
	tgggtgaaagt	aaaagatgct	gaagatcagt	tgggtgcacg	agtgggttac	atcgaaactg	2760
	atctcaacag	cggtaagatc	cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	2820
	gcacttttaa	agttctgcta	tgtggcgcg	tattatcccg	tgttgacgcc	gggcaagagc	2880
40	aactcggctg	ccgcatacac	tattctcaga	atgacttgg	tgagtactca	ccagtcacag	2940
	aaaagcatct	tacggatggc	atgacagtaa	gagaattatg	cagtgtctgc	ataaccatga	3000
	gtgataacac	tcgggccaac	ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	3060
	cttttttgca	caacatgggg	gatcatgtaa	ctcgcttga	tcgttgggaa	ccggagctga	3120
	atgaagccat	accaaacgac	gagcgtgaca	ccacgatgcc	tgtagcaatg	gcaacaacgt	3180
45	tgcgcaaaat	attaactggc	gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	3240
	ggatggaggc	ggataaagtt	gcaggaccac	ttctgcgctc	ggcccttcgc	gctggctggt	3300
	ttattgctga	taaatctgga	gcgggtgagc	gtgggtctcg	cgggtatcatt	gcagcactgg	3360
	ggccagatgg	taagccctcc	cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	3420
	tggatgaacg	aaatagacag	atcgctgaga	taggtgcctc	actgattaag	cattggtaac	3480
50	tgtcagacca	agtttactca	tatatacttt	agattgattt	aaaacttcat	ttttaattta	3540
	aaaggatcta	ggtgaagatc	cttttttgata	atctcatgac	caaaatccct	taacgtgagt	3600
	tttcggtcca	ctgagcgtca	gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	3660
	tttttctgcg	cgtaatctgc	tgcttgcaaa	caaaaaaac	accgctacca	gcggtggttt	3720
	gtttgcccga	tcaagagcta	ccaactcttt	ttccgaagg	aactggcttc	agcagagcgc	3780
55	agataccaaa	tactgtcctt	ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	3840
	tagcaccgcc	tacatacctc	gctctgctaa	tcctgttacc	agtggctgct	gccagtggcg	3900

EP 1 035 209 A1

	ataagtcgtg	tcttaccggg	ttggactcaa	gacgatagtt	accggataag	gcgcagcggg	3960
	cgggctgaac	gggggggttcg	tgcacacagc	ccagcttgga	gcgaacgacc	tacaccgaac	4020
	tgagatacct	acagcgtgag	ctatgagaaa	gcgccacgct	tcccgaagg	agaaaggcgg	4080
5	acaggtatcc	ggtaagcggc	agggctcgaa	caggagagcg	cacgaggag	cttccagggg	4140
	gaaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	4200
	ttttgtgatg	ctcgtcaggg	gggaggagcc	tatggaaaaa	cgccagcaac	gcggcctttt	4260
	tacggttcct	ggccttttgc	tggccttttg	ctcacatgtt	ctttcctgcg	ttatccccctg	4320
	attcattaat	gcaggtcacg	atc				4343
10	<210>	9					
	<211>	3888					
	<212>	DNA					
	<213>	Influenza virus					
15	<400>	9					
	ccccaaaaaa	aaaaaaaaaa	aaaaaaaaag	agtccagagt	ggccccgccc	ttccgcgcgc	60
	gggggggggg	ggggggggga	cacttttcgga	catctgggtcg	acctccagca	tcgggggaaa	120
	aaaaaaaaaac	aaagtttcgc	ccggagtgact	ggtcgacctc	cgaagttggg	ggggagtaga	180
20	aacagggttag	ataatcactc	actgagtgac	atccacatcg	cgagcgcgcg	taatacgact	240
	cactataggg	cgaattgggt	accgggcccc	ccctcgaggt	cgacgggtatc	gataagcttc	300
	gacgagattt	tcaggagcta	aggaagctaa	aatggagaaa	aaaatcactg	gatataccac	360
	cgttgatata	tcccaatggc	atcgtaaaga	acattttgag	gcatttcagt	cagttgctca	420
	atgtacctat	aaccagaccg	ttcagctgga	tattacggcc	tttttaaaga	ccgtaaagaa	480
25	aaataagcac	aagttttata	cgccctttat	tcacattctt	gcccgcctga	tgaatgctca	540
	tcgggaattc	cgtatggcaa	tgaaagacgg	tgagctgggtg	atatgggata	gtgttcaccc	600
	ttgttacacc	gttttccatg	agcaaaactga	aacgttttca	tcgctctgga	gtgaatacca	660
	cgacgatttc	cggcagtttc	tacacatata	ttcgcaagat	gtggcgtgtt	acggtgaaaa	720
	cctggcctat	ttccctaaag	ggttttattga	gaatatgttt	ttcgtctcag	ccaatccctg	780
	ggtgagtttc	accagttttg	atttaaacgt	ggccaatatg	gacaacttct	tcgccccctg	840
30	tttcaccatg	ggcaaatatt	atacgcaagg	cgacaagggtg	ctgatgccgc	tgggcattca	900
	ggttcatcat	gccgtttgtg	atggcttcca	tgtcggcaga	atgcttaatg	aattacaaca	960
	gtactcgcag	ggtatggcag	gcggggcgta	attttttaa	ggcagttatt	ggtgccccta	1020
	aacgcctggg	gctacgcctg	aataagtgat	aataagcgga	tgaatggcag	aaattcgctg	1080
	aagcttgata	tcgaattcct	gcagcccggg	ggatccacta	gttctagagc	ggccgccacc	1140
35	gcggtggagc	tcagctttt	gttcccttta	gtgagggtta	attgcgcgca	ggcctagcta	1200
	ggtaaagaaa	aatacccttg	attcttctaa	taaccggcg	gccccaaatg	ccgactcgga	1260
	gcgaaagata	tacctcccc	ggggccggga	ggtcgcgtca	ccgaccacgc	cgccggccca	1320
	ggcgacgcgc	gacacggaca	cctgtcccca	aaaacgccac	catcgcagcc	acacacggag	1380
	cgccccgggc	cctctggtca	accccaggac	acacgcggga	gcagcgcggg	gccggggacg	1440
40	ccctcccggc	cgcccgtgcc	acacgcaggg	ggccggcccc	tgtctccaga	gcggggagccg	1500
	gaagcatttt	cgcccgcccc	ctcctacgac	cgggacacac	gagggaccga	aggccggcca	1560
	ggcgcgacct	ctcgggccc	acgcgcgctc	agggagcgct	ctccgactcc	gcacggggac	1620
	tcgccagaaa	ggatcgtgac	ctgcattaat	gaatcagggg	ataacgcagg	aaagaacatg	1680
	tgagcaaaaag	gccagcaaaa	ggccaggaac	cgtaaaaagg	ccgcgttgct	ggcgtttttc	1740
45	cataggctcc	gccccctga	cgagcatcac	aaaaatcgac	gctcaagtca	gagggtggcga	1800
	aaccgcagac	gactataaag	ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	1860
	cctgttccga	ccctgccgct	taccggatac	ctgtccgcct	ttctcccttc	gggaagcgtg	1920
	gcgctttctc	atagctcacg	ctgtaggtat	ctcagttcgg	tgtaggtcgt	tcgctccaag	1980
	ctgggctgtg	tgacacgaac	ccccgttcag	cccgaccgct	gcgccttata	cggtaactat	2040
50	cgtcttgagt	ccaaccgggt	aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	2100
	aggattagca	gagcgaggta	tgtaggcggg	gctacagagt	tcttgaagtg	gtggccctaac	2160
	tacggctaca	ctagaaggac	agtatttggg	atctgcgctc	tgctgaagcc	agttaccttc	2220
	ggaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	ccgctggtag	cgggtggtttt	2280
	tttgtttgca	agcagcagat	tacgcgcaga	aaaaaaggat	ctcaagaaga	tcctttgatc	2340
55	ttttctacgg	ggtctgacgc	tcagtggaaac	gaaaactcac	gttaagggat	tttgggtcatg	2400

EP 1 035 209 A1

	agattatcaa	aaaggatctt	cacctagatc	cttttaaatt	aaaaatgaag	ttttaaatca	2460
	atctaaagta	tatatgagta	aacttggtct	gacagttacc	aatgcttaat	cagtgaggca	2520
	cctatctcag	cgatctgtct	atttcgttca	tccatagttg	cctgactccc	cgtcgtgtag	2580
5	ataactacga	tacgggaggg	cttaccatct	ggccccagtg	ctgcaatgat	accgcgagac	2640
	ccacgctcac	cggtctccaga	tttatcagca	ataaaccagc	cagccggaag	ggccgagcgc	2700
	agaagtgggc	ctgcaacttt	atccgcctcc	atccagtcta	ttaattgttg	ccgggaagct	2760
	agagtaagta	gttcgccagt	taatagtttg	cgcaacgttg	ttgccattgc	tacaggcatc	2820
	gtggtgtcac	gctcgctcgtt	tggtatggct	tcaatcagct	ccggttccca	acgatcaagg	2880
10	cgagttacat	gatcccccat	gttgtgcaaa	aaagcgggta	gtccttcggg	tcctccgcatc	2940
	gttgtcagaa	gtaagttggc	cgcagtggtta	tcaactcatgg	ttatggcagc	actgcataat	3000
	tctcttactg	tcatgccatc	cgtaagatgc	ttttctgtga	ctggtgagta	ctcaaccaag	3060
	tattcttgag	aatagtgtat	gcggcgaccg	agttgctctt	gcccggcgtc	aacacgggat	3120
	aataccgcgc	cacatagcag	aactttaaaa	gtgctcatca	ttggaaaacg	ttcttcgggg	3180
15	cgaaaactct	caaggatctt	accgctgttg	agatccagtt	cgatgtaacc	cactcgtgca	3240
	cccaactgat	cttcagcatc	ttttactttc	accagcgttt	ctgggtgagc	aaaaacagga	3300
	aggcaaaatg	ccgcaaaaaa	gggaataagg	gcgacacgga	aatgttgaat	actcatactc	3360
	ttcctttttc	aatattattg	aagcatttat	cagggttatt	gtctcatgag	cggatacata	3420
	tttgaatgta	tttagaaaaa	taaacaaaag	agtttgtaga	aacgcaaaaa	ggccatccgt	3480
20	caggatggcc	ttctgcttaa	tttgatgcct	ggcagtttat	ggcgggcgtc	ctgcccgcga	3540
	ccctccgggc	cgttgcttcg	caacgttcaa	atccgctccc	ggcggatttg	tcctactcag	3600
	gagagcgttc	accgacaaac	aacagataaa	acgaaaggcc	cagtctttcg	actgagcctt	3660
	togttttatt	tgatgcctgg	cagttcccta	ctctcgcag	gggagacccc	acactaccat	3720
	cggcgctacg	gcgtttcact	tctgagttcg	gcagggggtc	aggtgggacc	accgcgctac	3780
25	tgccgccagg	caaattctgt	tttatcagac	cgcttctgcg	ttctgattta	atctgtatca	3840
	ggctgaaaa	cttctctcat	ccgccaaaa	agaagctagc	ggccgac		3888

30

35

40

45

50

55

Claims

1. A recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; wherein
 - (a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or
 - (b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or *vice versa*, in overall convergent arrangement.
2. The recombinant virus according to claim 1, wherein in the ambisense RNA molecule said foreign recombinant gene is covalently bound to one of the viral genes, while the original vRNA segment coding for the same gene is deleted from the recombinant virus by way of specific ribozyme cleavage.
3. The recombinant virus according to claims 1 and 2 in which one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged into foreign glycoprotein(s) or into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.
4. The recombinant virus according to claims 1 to 3, in which the terminal viral RNA sequences, which are active as the promoter signal, have been varied by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence.
5. The recombinant virus according to claims 1 to 4, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code for proteins and/or glycoproteins which are secreted from cells infected with the recombinant virus.
6. The recombinant virus according to claims 1 to 4, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code for proteins or artificial polypeptides designed to support an efficient presentation of inherent epitopes at the surface of (abortively) infected cells, for stimulation of a B cell and/or T cell response.
7. A method for the production of recombinant influenza viruses as defined in claims 1 to 6 comprising
 - (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,
 - (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA segments, and
 - (c) thereafter selective vRNA inactivation through ribozyme cleavage.
8. A method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising
 - (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;
 - (b) followed by infection of an influenza wildtype strain;
 - (c) thereafter amplification through simple steps of viral propagation; and
 - (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing ribozyme type 2, followed by plaque purification.
9. A ribozyme-sensitive influenza carrier strain obtainable by the method of claim 8.
10. A pharmaceutical composition comprising a recombinant virus according to claims 1 to 6.
11. Use of a recombinant virus according to claims 1 to 6 for preparing a medicament for vaccination purposes.

12. The use according to claim 11, wherein the medicament

- (a) is suitable against influenza and/or against other infections;
- (b) is present in form of inactivated preparations; and/or
- (c) is present in form of live recombinant (attenuated) viruses.

13. Use of a recombinant virus according to claims 1 to 6 as vector systems in somatic gene therapy, for transfer and expression of foreign genes into cells (abortively) infected by such viruses, either in *ex vivo* or *in vivo* application schemes.

14. A method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus according to claims 1 to 6 as expression vector.

15. The method of claim 14, wherein the production is performed in cell culture cells or in fertilized chicken eggs.

FIG. 1




FIG. 2





FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8






FIG. 9

cRNA-promoter



PLASMIDS	MOCK	PHL1844	PHL2583	PHL2721	PHL2739	PHL2743	PHL2740	PHL2742	PHL2757
cRNA-promoter		1104	1104	3/8 T/A	3/8 A/T	12 T	11 A	12/11 T/A	



CAT-ACTIVITY (%)	3>	100	45	34	65	36	6	40	57
---------------------	----	-----	----	----	----	----	---	----	----

FIG. 10




FIG. 11




FIG. 12




FIG. 13



FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19





FIG. 20





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 99 10 4519

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
X	DE 197 09 512 A (HOBOM GERD PROF DR DR) 10 September 1998 (1998-09-10)	1,3,4, 7-14	C12N15/86 C12N7/01
Y	* the whole document *	2,5,6,15	C12N5/10 A61K39/00
X	WO 91 03552 A (SINAI SCHOOL MEDICINE) 21 March 1991 (1991-03-21)	1,10-15	A61K39/145 A61K48/00
Y	* figure 11; example 7 *	2,5,6	
Y	TAKASE H. ET AL: "Antibody responses and protection in mice immunized orally against influenza virus." VACCINE, vol. 14, no. 17/18, 1996, pages 1651-1656, XP002110225 * page 1652, left-hand column, paragraph 1 *	15	
X	ZHOU Y. ET AL.: "Membrane-anchored incorporation of a foreign protein in recombinant Influenza virions." VIROLOGY, vol. 246, 20 June 1998 (1998-06-20), pages 83-94, XP002110226 * the whole document *	1,10-14	
			TECHNICAL FIELDS SEARCHED
			C12N A61K
INCOMPLETE SEARCH The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search THE HAGUE		Date of completion of the search 26 July 1999	Examiner Mandl, B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/82 (P04C07)



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number
EP 99 10 4519

Although claim 13 and claim 14, as far as an in vivo application is concerned, are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 10 4519

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	PALESE P. ET AL.: "Negative-strand RNA viruses: Genetic engineering and applications." PROC. NATL. ACAD. SCI. U.S.A., vol. 93, October 1996 (1996-10), pages 11354-11358, XP000196755 * page 11354, right-hand column, last paragraph - page 11356, right-hand column, paragraph F *	1,10-14	
X	ZOBEL A. ET AL.: "RNA polymerase I catalysed transcription of insert viral cDNA." NUCLEIC ACIDS RESEARCH, vol. 21, no. 16, 1993, pages 3607-3614, XP002110227 * page 3607, right-hand column, paragraph 2 * * page 3612, right-hand column, paragraph 2 - page 3613, left-hand column, line 1 * * page 3614, left-hand column, paragraph 2 * -----	1,10	TECHNICAL FIELDS SEARCHED

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 10 4519

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-07-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19709512 A	10-09-1998	NONE	
WO 9103552 A	21-03-1991	US 5166057 A	24-11-1992
		AT 126272 T	15-08-1995
		AU 636916 B	13-05-1993
		AU 6411890 A	08-04-1991
		CA 2065245 A	01-03-1991
		DE 69021575 D	14-09-1995
		DE 69021575 T	14-12-1995
		DK 490972 T	30-10-1995
		EP 0490972 A	24-06-1992
		ES 2075901 T	16-10-1995
		GR 90100639 A	30-12-1991
		JP 5500607 T	12-02-1993
		PT 95124 A	18-04-1991
		US 5252289 A	12-10-1993
		US 5578473 A	26-11-1996
		US 5854037 A	29-12-1998
		US 5840520 A	24-11-1998
		US 5786199 A	28-07-1998
		US 5820871 A	13-10-1992